



CCC

CATEGORY:

CHEMICAL



ADDRESS
CONTACT IF FOUND:

03-02-00

Docket No. 60849/JPW/JML

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

February 29, 2000

Box: Patent Application

S I R:

Transmitted herewith for filing are the specification and claims of the patent application of:

Paul B. Fisher, Dong-Chul Kang and Rahul V. Gopalkrishnan
Inventor(s) forMELANOMA DIFFERENTIATION ASSOCIATED GENE-5 (Mda-5), PROMOTER AND USES THEREOF
Title of Invention

Also enclosed are:

☒ 19 sheet(s) of ☐ informal ☒ formal drawings.☒ Oath or declaration of Applicant(s).☒ A power of attorney☐ An assignment of the invention to _____☒ A Preliminary Amendment☒ A verified statement to establish small entity status under 37 C.F.R. §1.9 and §1.27.

The filing fee is calculated as follows:

CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT

	NUMBER FILED		NUMBER EXTRA*		RATE		FEE	
					SMALL ENTITY	OTHER ENTITY	SMALL ENTITY	OTHER ENTITY
TOTAL CLAIMS	20 -20	=	0	X	\$ 9	\$ 18	= \$ 0	\$ --
Independent Claims	3 -3	=	0	X	\$ 39	\$ 78	= \$ 0	\$ --
Multiple Dependent Claims Presented:					\$ 130	\$260	= \$ 0	\$ --
					BASIC FEE		\$ 345	\$ 760
					TOTAL FEE		\$ 345	\$ --

* If the difference in Col. 1 is less than zero, enter "0" in Col. 2

02/29/00


1c674 U.S. PTO
09/515363

Applicants: Paul B. Fisher, Dong-Chul Kang and Rahul V. Gopalkrishnan
Serial No.: Not Yet Known
Filed: February 29, 2000

Letter of Transmittal
Page 2

- ☒ A check in the amount of \$ 345.00 to cover the filing fee.
- ☐ Please charge Deposit Account No. _____ in the amount of \$ _____.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the following or credit any over-payment to Account No. 03-3125;
- ☒ Filing fees under 37 C.F.R. §1.16.
- ☒ Patent application processing fees under 37 C.F.R. §1.17.
- ☐ The issue fee set in 37 C.F.R. §1.18 at or before mailing of the Notice of Allowance, pursuant to 37 C.F.R. §1.311(b).
- ☒ Three copies of this sheet are enclosed.
- ☐ A certified copy of previously filed foreign application No. _____ filed in _____ on _____ Applicant(s) hereby claim priority based upon this aforementioned foreign application under 35 U.S.C. §119.
- ☒ Other (identify) Express Mail Certificate of Mailing bearing Label
No.: EL 278 886 053 US, dated February 29, 2000.
One loose set of formal drawings.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicant(s)
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

Applicant or Patentee: Paul B. Fisher, Dong-Chul Kang and Attorney's JPW/JML
Serial or Patent No.: Rahul V. Gopalkrishnan Docket No: 0575/60849
Filed or Issued: Not Yet Known
Title of Invention or Patent: Herewith
MELANOMA DIFFERENTIATION ASSOCIATED GENE -5 (Mda-5),
PROMOTER AND USES THEREOF

VERIFIED STATEMENT (DECLARATION) CLAIMING
SMALL ENTITY STATUS UNDER 37 C.F.R. §1.9(f)
AND §1.27(d) - NONPROFIT ORGANIZATION

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

Name of Organization: The Trustees of Columbia University
Address of Organization: Broadway and West 116th Street
New York, New York 10027

TYPE OF ORGANIZATION:

☒ UNIVERSITY OR OTHER INSTITUTION OF HIGHER EDUCATION
TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE 26 U.S.C. §§501(a) and 501(c)(3)
☐ NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA
NAME OF STATE: _____
CITATION OF STATUTE: _____
☐ WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE 26 U.S.C. §§501(a) and 501(c)(3) IF LOCATED IN THE UNITED STATES OF AMERICA
☐ WOULD QUALIFY AS NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA IF LOCATED IN THE UNITED STATES OF AMERICA
NAME OF STATE: _____
CITATION OF STATUTE: _____

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 C.F.R. §1.9(e)* for purposes of paying reduced fees under 35 U.S.C. §41(a) and 41(b), with regard to the invention entitled

by inventor(s) Paul B. Fisher, Dong-Chul Kang and Rahul V. Gopalkrishnan
described in:

☒ the specification filed herewith
☐ application serial no. _____ filed _____
☐ patent no. _____ issued _____

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above identified invention.

If the rights held by the nonprofit organization are not exclusive each individual, concern, or organization known to have rights to the invention is listed below^a and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 C.F.R. §1.9(d)* or a nonprofit organization under 37 C.F.R. §1.9(e)*

^aNOTE: Separate verified statements are required from each person, concern, or organization having rights to the invention averring to their status as small entities. 37 C.F.R. §1.27.

Name: _____
Address: _____

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

(d) A small business concern as used in this chapter means any business concern as defined by the Small Business Administration in 13 C.F.R. §121.3-18, published on September 30, 1982 at 47 FR 43273. For the convenience of the users of these regulations, that definition states:

§121.3-18 Definition of small business for paying reduced patent fees under Title 35, U.S. Code.

(a) Pursuant to Pub. L. 97-247, a small business concern for purposes of paying reduced fees under 35 U.S. Code 41(a) and (b) to the Patent and Trademark Office means any business concern (1) whose number of employees, including those of its affiliates, does not exceed 500 persons and (2) which has not assigned, granted, conveyed, or licensed, and is under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who could not be classified as an independent inventor if that person had made the invention, or to any concern which would not qualify as a small business concern or a nonprofit organization under this section. For the purpose of this section concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both. The number of employees of the business concern is the average over the fiscal year of the persons employed during each of the pay periods of the fiscal year. Employees are those persons employed on a full-time, part-time or temporary basis during the previous fiscal year of the concern.

(b) If the Patent and Trademark Office determines that a concern is not eligible as a small business concern within this section, the concern shall have a right to appeal that determination to the Small Business Administration. The Patent and Trademark Office shall transmit its written decision and the pertinent size determination file to the SBA in the event of such adverse determination and size appeal. Such appeals by concerns should be submitted to the SBA at 1441 L Street, NW., Washington, D.C. 20416 (Attention: SBA Office of General Counsel). The appeal should state the basis upon which it is claimed that the Patent and Trademark Office initial size determination on the concern was in error; and the facts and arguments supporting the concern's claimed status as a small business concern under this section.

(e) A nonprofit organization as used in this chapter means (1) a university or other institution of higher education located in any country; (2) an organization of the type described in section 501(c)(3) of the Internal Revenue Code of 1954 (26 U.S.C. 501(c)(3)) and exempt from taxation under section 501(a) of the Internal Revenue Code (26 U.S.C. 501(a)); (3) any nonprofit scientific or educational organization qualified under a nonprofit organization statute of a state of this country (35 U.S.C. 201(i); or (4) any nonprofit organization located in a foreign country which would qualify as a nonprofit organization under paragraphs (e)(2) or (3) of this section if it were located in this country.

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. 37 C.F.R. §1.28(b)*.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Name of Person Signing: Jack M. Granowitz
Title In Organization: Executive Director
Address: Columbia University, Engineering Terrace - Suite 363
Amsterdam Avenue & West 120th Street, New York, NY 10027
Signature: *Jack M. Granowitz*
Date Of Signature: 2/24/90

37 C.F.R. §1.28(b)

(b) Once status as a small entity has been established in an application or patent, fees as a small entity may thereafter be paid in that application or patent without regard to a change in status until the issue fee is due or any maintenance fee is due. Notification of any change in status resulting in loss of entitlement to small entity status must be filed in the application or patent prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate pursuant to §1.9 of this part. The notification of change in status may be signed by the applicant, any person authorized to sign on behalf of the assignee, or an attorney or agent of record or acting in a representative capacity pursuant to §1.34(a) of this part.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203

*Application
for
United States Letters Patent*

To all whom it may concern:

Be it known that **Paul B. Fisher, Dong-Chul Kang and Rahul V. Gopalkrishnan**

have invented certain new and useful improvements in

MELANOMA DIFFERENTIATION ASSOCIATED GENE-5 (Mda-5), PROMOTER AND USES THEREOF

of which the following is a full, clear and exact description.

Melanoma Differentiation Associated
Gene - 5 and Promoter and Uses Thereof

The invention disclosed herein was made with Government support under National Institutes of Health Chernow Endowment No. CA 74468-01 from the U.S. Department of Health and Human Services. Accordingly, the U.S. Government has certain rights in this invention.

Background of the Invention

Throughout this application, various publications are referenced by author and date within the text. Full citations for these publications may be found listed alphabetically at the end of the specification immediately preceding the claims. All patents, patent applications and publications cited herein, whether supra or infra, are hereby incorporated by reference in their entirety. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date of the invention described and claimed herein.

Abnormalities in differentiation are common occurrences in human cancers ((1)Fisher and Grant, 1985; (2) Waxman, 1995). Moreover, as cancer cells evolve, ultimately developing new phenotypes or acquiring a further elaboration of preexisting transformation-related properties, the degree of expression of differentiation-associated traits often undergo a further decline. These observations have been exploited as a novel means of cancer therapy in which tumor cells are treated with agents that induce differentiation and a loss of cancerous properties, a strategy called 'differentiation therapy' ((2-4) Waxman et al., 1988, 1991;

5 Jiang et al., 1994; Waxman, 1995). In principle, differentiation therapy may prove less toxic than currently employed chemotherapeutic approaches, including radiation and treatment with toxic chemicals. The ability to develop rational schemes for applying differentiation therapy clinically require appropriate in vitro and in vivo model systems for identifying and characterizing the appropriate agent or agents that can modulate differentiation in cancer cells without causing undue toxicity to normal cells.

Summary of the Invention

The invention provides for an isolated nucleic acid encoding *Mda-5* polypeptide as shown in SEQ ID NO:1. A polypeptide having the sequence shown in SEQ ID NO:2.

The present invention provides for an isolated *Mda-5* promoter capable of directing transcription of a heterologous coding sequence positioned downstream therefrom, wherein the promoter is selected from the group consisting of: (a) a promoter comprising the nucleotide sequence shown in SEQ ID NO:3 ; (b) a promoter comprising a nucleotide sequence functionally equivalent to the nucleotide sequence shown in SEQ ID NO: 3; and (c) a promoter comprising a nucleotide sequence that hybridizes to a sequence complementary to the promoter of (a) or (b) in a Southern hybridization reaction performed under stringent conditions. The invention provides for a host cell comprising the recombinant expression construct as described herein. The invention provides for a method for expressing foreign DNA in a host cell comprising: introducing into the host cell a gene transfer vector comprising an *Mda-5* promoter nucleotide sequence operably linked to a foreign DNA encoding a desired polypeptide or RNA, wherein said foreign DNA is expressed. The invention further provides for a method for treating cancer in a subject suffering therefrom which comprises administering to the subject an effective amount of a pharmaceutical composition which comprises a recombinant expression construct comprising: (a) a nucleic acid molecule that encodes a selected polypeptide; and (b) an *Mda-5* promoter nucleotide sequence operably linked to the nucleic acid molecule of element (a), wherein the coding sequence will be transcribed and translated when in a host cell to produce the selected polypeptide, and the *Mda-5* promoter is heterologous to the coding sequence and a pharmaceutically acceptable carrier.

Brief Description of the Figures

Figures 1A-1D. Sequence of mda-5 and alignment with CARD and RNA helicases. Figure 1A. Nucleotide sequence (SEQ ID NO:1) and corresponding amino acid sequence (SEQ ID NO:2) of mda-5. Underlined sequences are AUUUA sequences. Bold face sequence is the poly A signal. Figure 1B. Additional nucleotide sequence of mda-5p (SEQ ID NO:___). Poly A signal is bold faced. Figure 1C. Alignment of CARD proteins with 50 amino acids near the N-terminal region of MDA-5 (a.a. 125-174 correspond to 1-50). (SEQ ID NOS:___ - ___) Figure 1D. Alignment of the RNA helicase conserved motif of mda-5 with eIF-4A (SEQ ID NO:___) and p68 RNA helicases-2E (SEQ ID NO:___).

Figures 2A-2B. Northern blot analysis of mda-5 expression by various compounds inducing differentiation in HO-1 human melanoma cells. RNA samples were extracted from cells treated as indicated for 24 hr. Figure 2A. HO-1 human melanoma cells. Figure 2B. Early passage human skin fibroblast cells. Northern hybridization was performed as in Materials and Methods. Abbreviations and concentration of the indicated reagents are as follows: ctl, control; DMSO, 0.1% dimethyl sulfoxide; EtOH, 0.25% final concentration of ethanol; Mez, mezerein 10 ng/ml; IFN- β , 2,000 U/ml interferon- β ; IFN- β + Mez, 2,000 U/ml interferon- β plus mezerein 10 ng/ml; IFN- γ , interferon- γ 100 U/ml; IFN- γ + Mez, interferon- γ 100 U/ml plus mezerein 10 ng/ml; RA, all-trans-retinoic acid 2.5 B5M (dissolved in EtOH): MPA, mycophenolic acid 3 B5M; TPA, 12-O-tetradecanoylphorbol-13-acetate 16 nM; cAMP, 3'-5' cyclic adenosine monophosphate 1 mM; 8-Br-cAMP, 8-bromo-3'-5' cyclic adenosine monophosphate 1 mM; MMS, methylmethane sulfonate 10 ng/ml; poly IC 10 μ g/ml.

Figure 3. Northern blot analysis of mda-5 expression induced by

IFN- β in normal and tumor cell lines. RNA samples were extracted from the indicated cells treated with 2,000 U/ml of interferon- β for 24 hr. Northern hybridization was performed as in Materials and Methods.

Figures 4A-4B. Northern blot analysis of mda-5 expression by ligands for various membrane receptors. RNA samples were extracted from cells treated as indicated for 24 hr. Figure 4A. HO-1 human melanoma cells. Figure 4B. Early passage human skin fibroblast cells. Northern hybridization was performed as in Materials and Methods. Abbreviations and concentrations of indicated reagents are as follows: ctl, control; IFN- α , 1,000 U/ml interferon- α IFN- β , 1,000 U/ml interferon- β IFN- γ , 1,000 U/ml interferon- γ , IL-6, interleukin-6, 1 ng/ml; EGF, epidermal growth factor, 10 ng/ml; TGF- α , transforming growth factor α , 10 ng/ml; TGF- β transforming growth factor β , 2.5 ng/ml; TNF- α , tumor necrosis factor α , 10 ng/ml; PDGF, platelet-derived growth factor, 10 ng/ml.

Figure 5. Northern blot analysis and time course of mda-5 expression. RNA samples were extracted from HO-1 cells treated with the indicated reagents and harvested at the indicated time after treatment. Northern blotting was performed as in Materials and Methods. Abbreviations and concentrations of the indicated reagents are as follows: Mez, mezerein 10 ng/ml; IFN- β , 2,000 U/ml interferon- β ; IFN- β + Mez, 2,000 U/ml interferon- β plus mezerein 10 ng/ml.

Figure 6. Northern blot analysis of mda-5 expression in different organs. Multiple tissue Northern blots were purchased from ClonTech. Each lane contains 2 μ g of poly A+ RNA. Northern hybridization was performed as described in Materials and Methods.

Figures 7A-7C. Mechanism of induction of mda-5 expression. A.

Northern blot analysis of mda-5. HO-1 melanoma cells were treated with 5 μ g/ml actinomycin D 24 hr after incubation with 2,000 U/ml IFN- β or 2,000 U/ml IFN- β + 10 ng/ml Mez. Cells were harvested at the indicated time after actinomycin D treatment. Northern hybridization was performed as in Materials and Methods. Figure 7B. Nuclear run-on assays for determining mda-5 transcription rates. Nuclei were prepared from HO-1 melanoma cells treated with the indicated reagent(s) for 4 hr. Blots were prepared and hybridized as described in Materials and Methods. Abbreviations and concentrations of the indicated reagents are as follows: mda-5 5' and 3' fragment of mda-5 cDNA, respectively; ctl, control; Mez, mezerein 10 ng/ml; IFN- β , 2,000 U/ml interferon- β ; IFN- β + Mez, 2,000 U/ml interferon- β plus mezerein 10 ng/ml. Figure 7C. Northern blot analysis of mda-5 expression after blocking protein synthesis by cycloheximide (CHX). RNA samples were extracted from HO-1 melanoma cells pretreated with 50 μ g/ml cycloheximide for 30 min and treated with the indicated reagents for 8 hr. Abbreviations and concentrations of indicated reagents are as in Figure 4.

Figures 8A-8C. Protein expression of mda-5. Figure 8A. Autoradiogram of 9% SDS-PAGE of in vitro translated mda-5 cDNA. β -galactosidase was used as a positive control. Figure 8B. Western blot analysis of mda-5 fusion protein resolved in 9% SDS-PAGE. Protein extracts were prepared from 293T cells transiently transfected with the indicated expression vector. Details of transfection and immunoblot can be found in Materials and Methods. Figure 8C. Intracellular localization of mda-5 protein. Transiently transfected 293T cells with the indicated fusion protein constructs were mounted and observed by fluorescent confocal microscopy (400X).

Figure 9. The effect of ectopic expression of mda-5 on G418-resistant colony formation of HO-1 melanoma cells. HO-1

melanoma cells were transfected and selected with G418 as in Materials and Methods. Giemsa-stained colonies containing more than about 50 cells were counted. The results are mean \pm standard error from three independent transfections (three plates for each transfection) with two different plasmid batches.

Figure 10: The sequence of the proximal promoter region of the mda-5 gene showing landmark restriction sites. The initiator Methionine codon is highlighted by an open box as is the BstXI sites used to perform an internal deletion that removed the ATG as described in the text.

Figure 11: Screening of stable human HO-1 melanoma clones for promoter activity of stably integrated mda-5 reporter construct. Transfected HO-1 cells were selected by Puromycin drug selection and individual colonies analyzed for induction of luciferase activity in the presence of IFN- β . Values are expressed as fold change against uninduced values of luciferase activity.

Figure 12: Induction kinetics of mda-5 promoter activity. Stable clones #20 and #40 were treated with IFN- β and samples were harvested and analyzed for luciferase activity at the times indicated.

Figure 13: Responsiveness of the mda-5 promoter to IFN- β levels: Stable clones #20 and #40 were treated with IFN- β and samples were harvested and analyzed for luciferase activity 48h after initiation of treatment. The extent of activity was normalized based on equivalent protein content and performed in duplicate for each clone.

Figures 14A-14B: Responsiveness of the mda-5 promoter to various

inducers: Figure 14A. HO-1 cells transiently transfected with the mda-5 reporter and treated for 48h with equivalent units of IFNs α , β and γ and TNF- α and poly IC:IC. The luciferase activity was expressed as fold increase over untreated control cells. Figure 14B. Clone #40 was treated with equivalent units of the indicated IFNs for 48h and luciferase activity expressed as fold activation over untreated cells determined.

Figure 15: Induction kinetics of mda-5 promoter activity by double stranded RNA. Stable clones #20 and #40 were treated with 2 $\mu\text{g/ml}$ poly IC:IC and samples harvested and analyzed for luciferase activity at the times indicated.

Detailed Description of the Invention

The following abbreviations are used herein: *Mda-5* - Melanoma differentiation associated gene -5, CMV - cytomegalovirus,

The invention provides for an isolated nucleic acid comprising the sequence shown in SEQ ID NO: 1 encoding a Melanoma Differentiation Associated Gene -5 (*Mda-5*) polypeptide.

In one embodiment, the invention provides for an isolated nucleic acid comprising a derivative of the sequence of SEQ ID NO:1 encoding a polypeptide which is functionally equivalent to *Mda-5*.

The present invention also provides for a fragment of the isolated nucleic acid aforementioned, wherein the fragment encodes a polypeptide having *Mda-5* biological activity.

The invention provides for a nucleic acid which hybridizes to the DNA shown in SEQ ID NO:1 or the complementary strand thereof, wherein the nucleic acid or the complementary strand thereof, encodes a polypeptide having *Mda-5* activity.

The invention further provides for a vector comprising any of the nucleic acids described herein. In one embodiment, the vector is a replicable vector, a gene transfer vector, an expression vector, or a vector capable of driving expression of a gene of interest in a host cell.

The invention provides for a host cell comprising the aforementioned vector.

The invention provides a method for identifying a compound as an agonist or antagonist of interferon- β , interferon- α or interferon

y which comprises: (a) contacting a cell with the compound, wherein the cell comprises a nucleic acid having the sequence shown in SEQ ID NO:2, or a functional equivalent thereof, operably linked to a reporter gene; (b) measuring the level of reporter gene expressed by the cell in the presence of the compound; (c) comparing the expression level of the reporter gene measured in step (b) with the expression level of reporter gene measured in the absence of the compound, so as to identify whether the compound is an interferon agonist or antagonist; wherein a higher level of reporter gene expression measured in step (b) is indicative of the compound being an interferon agonist, and wherein a lower level of reporter gene expression measured in step (b) is indicative of the compound being an interferon antagonist.

In one embodiment, the compound is a small organic molecule having a weight of about 5 kilodaltons or less.

In another embodiment, the cell is a HO-1 human melanoma cell.

In another embodiment of the invention, the level of reporter gene expression measured which is indicative of an agonist is from 10 to 1000 fold higher than the level of reporter gene expression measured in the absence of the compound.

In another embodiment of the invention, the reporter gene is luciferase.

The invention provides for an isolated polypeptide having the amino acid sequence shown in SEQ ID NO:2 encoding Mda-5.

The invention also provides for an isolated antibody which specifically binds to the polypeptide having the sequence shown in SEQ ID NO:2.

In one embodiment, the antibody is a monoclonal antibody.

The invention provides for an isolated *Mda-5* promoter capable of directing transcription of a heterologous coding sequence positioned downstream therefrom, wherein the promoter is selected from the group consisting of: (a) a promoter comprising the nucleotide sequence shown in SEQ ID NO:3 ; (b) a promoter comprising a nucleotide sequence functionally equivalent to the nucleotide sequence shown in SEQ ID NO: 3; and (c) a promoter comprising a nucleotide sequence that hybridizes to a sequence complementary to the promoter of (a) or (b) in a Southern hybridization reaction performed under stringent conditions.

In one embodiment, the promoter comprises the nucleotide sequence shown in SEQ ID NO:3.

The invention provides for a recombinant expression construct effective in directing the transcription of a selected coding sequence which comprises: (a) an *Mda-5* promoter nucleotide sequence according to claim 15; and (b) a coding sequence operably linked to the promoter, whereby the coding sequence can be transcribed and translated in a host cell, and the promoter is heterologous to the coding sequence.

In one embodiment, the *Mda-5* promoter comprises a human *Mda-5* promoter.

In another embodiment, the human *Mda-5* promoter comprises the nucleotide sequence shown in SEQ ID NO:3.

In another embodiment, the coding sequence encodes a tumor suppressor polypeptide.

In another embodiment, the tumor suppressor polypeptide is p21, retinoblastoma protein or p53.

The invention provides for a host cell comprising the recombinant expression construct described herein. In one embodiment the host cell is stably transformed with the recombinant expression construct.

In another embodiment, the host cell is a tumor cell.

In another embodiment, the host cell is a melanocyte.

In another embodiment, the cell is an immortalized cell.

In another embodiment, the tumor cell is a melanoma cell, a neuroblastoma cell, an astrocytoma cell, a glioblastoma cell, a cervical cancer cell, a breast cancer cell, a lung cancer cell or a prostate cancer cell.

The invention provides for an isolated *Mda-5* promoter capable of directing the transcription of a heterologous coding sequence positioned downstream therefrom, wherein the promoter is selected from the group consisting of (a) a promoter comprising the nucleotide sequence shown in SEQ ID NO:3; (b) a promoter comprising a nucleotide sequence functionally equivalent to the promoter in element (a); and (c) a promoter comprising a nucleotide sequence that hybridizes to a sequence complementary to the promoter of element (a) or element (b) in a Southern hybridization reaction performed under stringent conditions.

The invention also provides for a method for treating cancer in a subject suffering therefrom which comprises administering to the subject an effective amount of a pharmaceutical composition which comprises a recombinant expression construct comprising:

- (a) a nucleic acid molecule that encodes a polypeptide of interest; and

(b) an *Mda-5* promoter nucleotide sequence operably linked to the nucleic acid molecule of element (a), and wherein the *Mda-5* promoter is heterologous to the nucleic acid molecule,
and a pharmaceutically acceptable carrier.

In one embodiment, the cancer is melanoma, neuroblastoma, astrocytoma, glioblastoma multiforme, cervical cancer, breast cancer, colon cancer, prostate cancer, osteosarcoma, or chondrosarcoma.

In one embodiment, the cancer is a cancer of the central nervous system of the subject.

In one embodiment, the administering is carried out via injection, oral administration, topical administration, adenovirus infection, liposome-mediated transfer, topical application to the cells of the subject, or microinjection.

In one embodiment, the carrier is an aqueous carrier, a liposome, or a lipid carrier.

mda-5 cDNA (SEQ ID NO:1)

```
GCGCGCCGGC CTGAGAGCCC TGTGGACAAC CTCGTCATTG TCAGGCACAG
AGCGGTAGAC CCTGCTTCTC TAAGTGGGCA GCGGACAGCG GCACGCACAT
TTCACCTGTC CCGCAGACAA CAGCACCATC TGCTTGGGAG AACCTCTCC
CTTCTCTGAG AAAGAAAGAT GTCGAATGGG TATTCCACAG ACGAGAATT
CCGCTATCTC ATCTCGTGCT TCAGGGCCAG GGTGAAAATG TACATCCAGG
TGGAGCCTGT GCTGGACTAC CTGACCTTTC TGCCTGCAGA GGTGAAGGAG
CAGATTGAGA GGACAGTCGC CACCTCCGGG AACATGCAGG CAGTTGAACT
GCTGCTGAGC ACCTTGGAGA AGGGAGTCTG GCACCTTGGT TGGACTCGGG
AATTCGTGGA GGCCCTCCGG AGAACCGGCA GCCCTCTGGC CGCCCGCTAC
```

ATGAACCCTG AGCTCACGGA CTTGCCCTCT CCATCGTTTG AGAACGCTCA
TGATGAATAT CTCCAACTGC TGAACCTCCT TCAGCCCCT CTGGTGGACA
AGCTTCTAGT TAGAGACGTC TTGGATAAGT GCATGGAGGA GGAAGTGTG
ACAATTGAAG ACAGAAACCG GATTGCTGCT GCAGAAAACA ATGGAATGA
5 ATCAGGTGTA AGAGAGCTAC TAAAAAGGAT TGTGCAGAAA GAAACTGGT
TCTCTGCATT TCTGAATGTT CTTCTGCAAA CAGGAAACAA TGAACTTGTC
CAAGAGTTAA CAGGCTCTGA TTGCTCAGAA AGCAATGCAG AGATTGAGAA
TTTATCACAA GTTGATGGTC CTCAAGTGGA AGAGCAACTT CTTTCAACCA
CAGTTCAGCC AAATCTGGAG AAGGAGGTCT GGGGCATGGA GAATAACTCA
10 TCAGAATCAT CTTTTCGAGA TTCTTCTGTA GTTTCAGAAT CAGACACAAG
TTTGGCAGAA GGAAGTGTCA GCTGCTTAGA TGAAAGTCTT GGACATAACA
GCAACATGGG CAGTGATTCA GGCACCATGG GAAGTGATT CAGATGAAGAG
AATGTGGCAG CAAGAGCATC CCCGGAGCCA GAACTCCAGC TCAGGCCTTA
CCAAATGGAA GTTGCCAGC CAGCCTTGGA AGGGAAGAAT ATCATCATCT
15 GCCTCCCTAC AGGGAGTGGA AAAACCAGAG TGGCTGTTTA CATTGCCAAG
GATCACTTAG ACAAGAAGAA AAAAGCATCT GAGCCTGGAA AAGTTATAGT
TCTTGTCAAT AAGGTAAGTC TAGTTGAACA GCTCTCCGC AAGGAGTTCC
AACCATTTT GAAGAAATGG TATCGTGTTA TTGGATTAA TGGTGATACC
CAACTGAAAA TATCATTTCC AGAAGTTGTC AAGTCCTGTG ATATTATTAT
20 CAGTACAGCT CAAATCCTTG AAAACTCCCT CTTAACTTG GAAAATGGAG
AAGATGCTGG TGTTCAATTG TCAGACTTTT CCCTCATTAT CATTGATGAA
TGTCATCACA CCAACAAAGA AGCAGTGTAT AATAACATCA TGAGGCATTA
TTTGATGCAG AAGTTGAAAA ACAATAGACT CAAGAAAGAA AACAAACCAG
TGATTCCCCT TCCTCAGATA CTGGGACTAA CAGCTTCACC TGGTGTGGGA
25 GGGGCCACGA AGCAAGCCAA AGCTGAAGAA CACATTTTAA AACTATGTGC
CAATCTTGAT GCATTTACTA TTAAACTGT TAAAGAAAAC CTTGATCAAC
TGAAAAACCA AATACAGGAG CCATGCAAGA AGTTTGCCAT TGCAGATGCA
ACCAGAGAAG ATCCATTTAA AGAGAAACTT CTAGAAATAA TGACAAGGAT
TCAAACCTAT TGTCAAATGA GTCCAATGTC AGATTTTGGA ACTCAACCCT
30 ATGAACAATG GGCCATTCAA ATGGAAAAA AAGCTGCAAA AAAAGGAAAT
CGCAAAGAAC GTGTTTGTGC AGAACATTTG AGGAAGTACA ATGAGGCCCT
ACAAATTAAT GACACAATTC GAATGATAGA TGCGTATACT CATCTTGAAA
CTTTCTATAA TGAAGAGAAA GATAAGAAGT TTGAGTCAT AGAAGATGAT
AGTGATGAGG GTGGTGATGA TGAGTATTGT GATGGTGATG AAGATGAGGA
35 TGATTTAAAG AAACCTTTGA AACTGGATGA AACAGATAGA TTTCTCATGA

CTTTATTTTT TGAAAAAACAAT AAAATGTTGA AAAGGCTGGC TGAAAAACCA
GAATATGAAA ATGAAAAGCT GACCAAATTA AGAAATACCA TAATGGAGCA
ATATACTAGG ACTGAGGAAT CAGCACGAGG AATAATCTTT AAAAAACAC
GACAGAGTGC ATATGCGCTT TCCCAGTGGA TTAAGTAAAA TGAAAAATTT
5 GCTGAAGTAG GAGTCAAAGC CCACCATCTG ATTGGAGCTG GACACAGCAG
TGAGTTCAAA CCCATGACAC AGAATGAACA AAAAGAAGTC ATTAGTAAAT
TTCGCACTGG AAAAATCAAT CTGCTTATCG CTACCACAGT GGCAGAAGAA
GGTCTGGATA TTAAAGAATG TAACATTGTT ATCCGTTATG GTCTCGTCAC
CAATGAAATA GCCATGGTCC AGGCCCGTGG TCGAGCCAGA GCTGATGAGA
10 GCACCTACGT CCTGGTTGCT CACAGTGGTT CAGGAGTTAT CGAACATGAG
ACAGTTAATG ATTTCCGAGA GAAGATGATG TATAAAGCTA TACATTGTGT
TCAAAATATG AAACCAGAGG AGTATGCTCA TAAGATTTTG GAATTACAGA
TGCAAAGTAT AATGGAAAAG AAAATGAAAA CCAAGAGAAA TATTGCCAAG
CATTACAAGA ATAACCCATC ACTAATAACT TTCCTTTGCA AAAACTGCAG
15 TGTGCTAGCC TGTCTGGGG AAGATATCCA TGTAATTGAG AAAATGCATC
ACGTCAATAT GACCCAGAA TTCAAGGAAC TTTACATTGT AAGAGAAAAC
AAAGCACTGC AAAAGAAGTG TGCCGACTAT CAAATAAATG GTGAAATCAT
CTGCAAATGT GGCCAGGCTT GGGGAACAAT GATGGTGCAC AAAGGCTTAG
ATTTGCCTTG TCTCAAAATA AGGAATTTTG TAGTGGTTTT CAAAAATAAT
20 TCAACAAAGA AACAATACAA AAAGTGGGTA GAATTACCTA TCACATTTCC
CAATCTTGAC TATTCAGAAT GCTGTTTATT TAGTGATGAG GATTAGCACT
TGATTGAAGA TTCTTTTAAA ATACTATCAG TTAAACATTT AATATGATTA
TGATTAATGT ATTCATTATG CTACAGAACT GACATAAGAA TCAATAAAAT
GATTGTTTCTA CTCTG

25

Mda-5 potein sequence (SEQ ID NO:2)

MSNGYSTDEN FRYLISCFRA RVKMYIQVEP VLDYLTFLLPA EVKEQIQRTV
ATSGNMQAVE LLLSTLEKGV WHLGWTRFV EALRRTGSPLE AARYMNPFLT
DLPSPSFENA HDEYLQLLNL LQPTLVDKLL VRDVLDKCME EELLTIEDRN
30 RIAAAENNGN ESGVRELLKR IVQKENWFSA FLNVLRLQTN NELVQELTGS
DCSESNAEIE NLSQVDGPQV EEQLLSTTVQ PNLEKEVWGM ENNSSESSFA
DSSVVSSEDV SLAEGSVSCL DESLGHSNM GSDSGTMGSD SDEENVAARA
SPEPELQLRP YQMEVAQPAL EGKNIIICLP TGSGKTRVAV YIAKDHLDDK
KKASEPGKVI VLVNKLVE QLFKEFQPF LKKWYRVIGL SGGTQLKISF

PEVVKSCDII ISTAQILENS LLNLENGEDA GVQLSDFS LI IIDECHHTNK
EAVYNNIMRH YLMQKLKNNR LKKENKPVIP LPQILGLTAS PGVGGATKQA
KAEHILKLC ANLDAFTIKT VKENLDQLKN QIQEPCKKFA IADATREDPF
KEKLEIMTR IQTYCQMSPM SDFGTQPYEQ WAIQMEKKAA KKGNRKERV
5 AEHLRKYNEA LQINDTIRMI DAYTHLETIFY NEEKDKKFAV IEDDSDEGGD
DEYCDGDEDE DDLKKPLKLD ETDRFLMTLF FENNKMLKRL AENPEYENEK
LTKLRNTIME QYTRTEESAR GIIFTKTRQS AYALSQWITE NEKFAEVGVK
AHLIGAGHS SEFKPMTQNE QKEVISKFR T GKNLLIATT VAEGLDIKE
CNIVIRYGLV TNEIAMVQAR GRARADESTY VLVAHSGSGV IEHETVNDFR
10 EKMMYKAIHC VQNMKPEEYA HKILELQMQS IMEKKMKTKR NIAKHYKNNP
SLITFLCKNC SVLACSGEDI HVIEKMHHVN MTPEFKELI VRENKALQKK
CADYQINGEI ICKCGQAWGT MMVHKGLDLP CLKIRNFVVV FKNNSTKKQY
KKWVELPITF PNLDYSECCL FSDDED•

15 The practice of the present invention will employ, unless otherwise
indicated, conventional techniques of molecular biology,
microbiology, virology, recombinant DNA technology, and immunology,
which are within the skill of the art. Such techniques are
20 explained fully in the literature. See, e.g., Sambrook, Fritsch &
Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition
(1989); DNA Cloning, Vols. I and II (D. N. Glover ed. 1985);
Oligonucleotide Synthesis (M. J. Gait ed. 1984); Nucleic Acid
Hybridization (B. D. Hames & S. J. Higgins eds. 1984); Animal Cell
25 Culture (R. K. Freshney ed. 1986); Immobilized Cells and Enzymes
(IRL press, 1986); Perbal, B., A Practical Guide to Molecular
Cloning (1984); the series, Methods In Enzymology (S. Colowick and
N. Kaplan eds., Academic Press, Inc.); and Handbook of Experimental
Immunology, Vols. I-IV (D. M. Weir and C. C. Blackwell eds., 1986,
30 Blackwell Scientific Publications).

As used in this specification and the appended claims, the singular
forms "a," "an" and "the" include plural references unless the
content clearly dictates otherwise.

The present invention provides for an isolated *Mda-5* promoter capable of directing transcription of a heterologous coding sequence positioned downstream therefrom, wherein the promoter is selected from the group consisting of: (a) a promoter comprising the nucleotide sequence shown in SEQ ID NO:___ ; (b) a promoter comprising a nucleotide sequence functionally equivalent to the nucleotide sequence shown in SEQ ID NO: ___; and (c) a promoter comprising a nucleotide sequence that hybridizes to a sequence complementary to the promoter of (a) or (b) in a Southern hybridization reaction performed under stringent conditions.

In one embodiment of the invention, the promoter comprises the nucleotide sequence shown in SEQ ID NO:___.

The present invention also provides for a recombinant expression construct effective in directing the transcription of a selected coding sequence which comprises:

(a) an *Mda-5* promoter nucleotide sequence as described herein; and

(b) a coding sequence operably linked to the promoter, whereby the coding sequence can be transcribed and translated in a host cell, and the promoter is heterologous to the coding sequence. In another embodiment of the invention, the *Mda-5* promoter comprises a human *Mda-5* promoter.

In another embodiment of the invention, the human *Mda-5* promoter comprises the nucleotide sequence shown in SEQ ID NO:3.

In another embodiment of the invention, the coding sequence encodes a tumor suppressor polypeptide.

In another embodiment of the invention, the tumor suppressor polypeptide is p21, retinoblastoma protein or p53.

The invention provides for a host cell comprising the recombinant expression construct as described herein.

5 In another embodiment of the invention, the host cell is stably transformed with the recombinant expression construct described herein.

10 In another embodiment of the invention, the host cell is a tumor cell.

In another embodiment of the invention, the host cell is a melanocyte.

15 In another embodiment of the invention, the cell is an immortalized cell.

20 In another embodiment of the invention, the tumor cell is a melanoma cell, a neuroblastoma cell, an astrocytoma cell, a glioblastoma cell, a glioblastoma multiforme cell, a cervical cancer cell, a breast cancer cell, a lung cancer cell or a prostate cancer cell.

25 The invention provides for a method for expressing foreign DNA in a host cell comprising: introducing into the host cell a gene transfer vector comprising an *Mda-5* promoter nucleotide sequence operably linked to a foreign DNA encoding a desired polypeptide or RNA, wherein said foreign DNA is expressed.

In another embodiment of the invention, the gene transfer vector encodes and expresses a reporter molecule.

30 In another embodiment of the invention, the reporter molecule is selected from the group consisting of beta-galactosidase, luciferase and chloramphenicol acetyltransferase.

In another embodiment of the invention, the "introducing" is carried out by a means selected from the group consisting of adenovirus infection, liposome-mediated transfer, topical application to the cell, and microinjection.

5 The invention provides for an isolated *Mda-5* promoter capable of directing the transcription of a heterologous coding sequence positioned downstream therefrom, wherein the promoter is selected from the group consisting of (a) a promoter comprising the
10 nucleotide sequence shown in SEQ ID NO:3; (b) a promoter comprising a nucleotide sequence functionally equivalent to the promoter in element (a); and (c) a promoter comprising a nucleotide sequence that hybridizes to a sequence complementary to the promoter of element (a) or element (b) in a Southern hybridization reaction
15 performed under stringent conditions.

The invention further provides for a method for treating cancer in a subject suffering therefrom which comprises administering to the subject an effective amount of a pharmaceutical composition which
20 comprises a recombinant expression construct comprising: (a) a nucleic acid molecule that encodes a selected polypeptide; and (b) an *Mda-5* promoter nucleotide sequence operably linked to the nucleic acid molecule of element (a), wherein the coding sequence will be transcribed and translated when in a host cell to produce
25 the selected polypeptide, and the *Mda-5* promoter is heterologous to the coding sequence and a pharmaceutically acceptable carrier.

30 In another embodiment of the invention, the cancer is melanoma, neuroblastoma, astrocytoma, glioblastoma multiforme, cervical cancer, breast cancer, colon cancer, prostate cancer, osteosarcoma, or chondrosarcoma.

In another embodiment of the invention, the cancer is a cancer of the central nervous system of the subject.

In another embodiment of the invention, the administering is carried out via injection, oral administration, or topical administration.

5 In another embodiment of the invention, the carrier is an aqueous carrier, a liposome, or a lipid carrier.

10 A method for determining whether a compound is an inducer of Mda-5 gene expression in a cell and an inducer of terminal differentiation of such cell which comprises: (a) contacting a cell with the compound, wherein the cell comprises a nucleic acid encoding Mda-5 having the sequence shown in SEQ ID NO:1, or a functional equivalent thereof, operably linked to an Mda-5 promoter; (b) measuring the level of either (i) Mda-5 mRNA produced or (ii) Mda-5 polypeptide expressed by the cell in the presence of the compound; (c) comparing the expression level of Mda-5 mRNA or polypeptide measured in step (b) with the level measured in the absence of the compound, so as to determine whether the compound is an inducer of Mda-5 gene expression and an inducer of terminal differentiation of the cell.

15 A method for treating cancer in a subject suffering therefrom which comprises administering to the subject an effective amount of a compound identified by the method of identifying an inducer of Mda-5 gene expression described herein and a pharmaceutically acceptable carrier, so as to induce terminal differentiation of the cancer cells in the subject and thereby treat the cancer.

Definitions

30

As used herein "therapeutic gene" means DNA encoding an amino acid sequence corresponding to a functional protein capable of exerting a therapeutic effect on cancer cells or having a regulatory effect on the expression of a function in cells.

As used herein "nucleic acid molecule" includes both DNA and RNA and, unless otherwise specified, includes both double-stranded and single-stranded nucleic acids. Also included are hybrids such as DNA-RNA hybrids. Reference to a nucleic acid sequence can also include modified bases as long as the modification does not significantly interfere either with binding of a ligand such as a protein by the nucleic acid or Watson-Crick base pairing.

As used herein "*Mda-5* promoter" means the promoter having about 1000 base pairs (bp) derived from the 5' flanking region of the *Mda-5* gene as shown in Figure 10. See SEQ ID NO:3 as follows.

Mda-5 cDNA (SEQ ID NO:1) and *Mda-5* polypeptide (SEQ ID NO:2)

Mda-5 cDNA (SEQ ID NO:1)

GCGCGCCGGC CTGAGAGCCC TGTGGACAAC CTCGTCATTG TCAGGCACAG
AGCGGTAGAC CCTGCTTCTC TAAGTGGGCA GCGGACAGCG GCACGCACAT
TTCACCTGTC CCGCAGACAA CAGCACCATC TGCTTGGGAG AACCTCTCTC
CTTCTCTGAG AAAGAAAGAT GTCGAATGGG TATTCCACAG ACGAGAATTT
CCGCTATCTC ATCTCGTGCT TCAGGGCCAG GGTGAAAATG TACATCCAGG
TGGAGCCTGT GCTGGACTAC CTGACCTTTC TGCCTGCAGA GGTGAAGGAG
CAGATTGAGA GGACAGTCGC CACCTCCGGG AACATGCAGG CAGTTGAACT
GCTGCTGAGC ACCTTGGAGA AGGGAGTCTG GCACCTTGGT TGGACTCGGG
AATTCTGTGA GGCCTCCGG AGAACCGGCA GCCCTCTGGC CGCCCGCTAC
ATGAACCTTG AGCTCACGGA CTTGCCCTCT CCATCGTTTG AGAACGCTCA
TGATGAATAT CTCCAACGTC TGAACCTCCT TCAGCCCACT CTGGTGGACA

AGCTTCTAGT TAGAGACGTC TTGGATAAGT GCATGGAGGA GGAAGTGTG
ACAATTGAAG ACAGAAACCG GATTGCTGCT GCAGAAAACA ATGGAAATGA
ATCAGGTGTA AGAGAGCTAC TAAAAAGGAT TGTGCAGAAA GAAAAGTGGT
TCTCTGCATT TCTGAATGTT CTTCGTCAA CAGGAAACAA TGAAGTTGTC
5 CAAGAGTTAA CAGGCTCTGA TTGCTCAGAA AGCAATGCAG AGATTGAGAA
TTTATCACAA GTTGATGGTC CTCAAGTGA AGAGCAACTT CTTTCAACCA
CAGTTCAGCC AAATCTGGAG AAGGAGGTCT GGGGCATGGA GAATAACTCA
TCAGAATCAT CTTTTGCAGA TTCTTCTGTA GTTTCAGAA CAGACACAAG
TTTGGCAGAA GGAAGTGTC GCTGCTTAGA TGAAAGTCTT GGACATAACA
10 GCAACATGGG CAGTGATTCA GGCACCATGG GAAGTGATT CAGATGAAGAG
AATGTGGCAG CAAGAGCATC CCCGGAGCCA GAACTCCAGC TCAGGCCTTA
CCAAATGGAA GTTGCCCAGC CAGCCTTGA AGGGAAGAAT ATCATCATCT
GCCTCCCTAC AGGGAGTGGA AAAACCAGAG TGGCTGTTTA CATTGCCAAG
GATCACTTAG ACAAGAAGAA AAAAGCATCT GAGCCTGGAA AAGTTATAGT
15 TCTTGTCAT AAGGTACTGC TAGTTGAACA GCTCTTCCG AAGGAGTTCC
AACCATTTTT GAAGAAATGG TATCGTGTTA TTGGATTAAG TGGTGATACC
CAACTGAAAA TATCATTTCC AGAAGTTGTC AAGTCCTGTG ATATTATTAT
CAGTACAGCT CAAATCCTTG AAAACTCCCT CTTAAACTTG GAAAATGGAG
AAGATGCTGG TGTTC AATTG TCAGACTTTT CCCTCATTAT CATTGATGAA
20 TGTCATCACA CCAACAAAGA AGCAGTGAT AATAACATCA TGAGGCATTA
TTTGATGCAG AAGTTGAAAA ACAATAGACT CAAGAAAGAA AACAAACCAG
TGATTCCCT TCCTCAGATA CTGGGACTAA CAGCTTCACC TGGTGTGGA
GGGGCCACGA AGCAAGCCAA AGCTGAAGAA CACATTTTAA AACTATGTGC
CAATCTTGAT GCATTTACTA TTAAACTGT TAAAGAAAAC CTTGATCAAC
25 TGAAAAACCA AATACAGGAG CCATGCAAGA AGTTTGCCAT TGCAGATGCA
ACCAGAGAAG ATCCATTTAA AGAGAAACTT CTAGAAATAA TGACAAGGAT

TCAAACTTAT TGTCAAATGA GTCCAATGTC AGATTTTGG AACTCAACCCT
ATGAACAATG GGCCATTCAA ATGGAAAAA AAGCTGCAAA AAAAGGAAAT
CGCAAAGAAC GTGTTTGTGC AGAACATTTG AGGAAGTACA ATGAGGCCCT
ACAAATTAAT GACACAATTC GAATGATAGA TCGTATACT CATCTTGAAA
5 CTTTCTATAA TGAAGAGAAA GATAAGAAGT TTGCAGTCAT AGAAGATGAT
AGTGATGAGG GTGGTGATGA TGAGTATTGT GATGGTGATG AAGATGAGGA
TGATTTAAAG AAACCTTTGA AACTGGATGA AACAGATAGA TTTCTCATGA
CTTTATTTTT TGAAAACAAT AAAATGTTGA AAAGGCTGGC TGAAAACCCA
GAATATGAAA ATGAAAAGCT GACCAAATTA AGAAATACCA TAATGGAGCA
10 ATATACTAGG ACTGAGGAAT CAGCACGAGG AATAATCTTT AAAAAACAC
GACAGAGTGC ATATGCGCTT TCCCAGTGGA TTACTGAAAA TGAAAAATTT
GCTGAAGTAG GAGTCAAAGC CCACCATCTG ATTGGAGCTG GACACAGCAG
TGAGTTCAAA CCCATGACAC AGAATGAACA AAAAGAAGTC ATTAGTAAAT
TTCGCACTGG AAAAATCAAT CTGCTTATCG CTACCACAGT GGCAGAAGAA
15 GGTCTGGATA TTAAAGAATG TAACATTGTT ATCCGTTATG GTCTCGTCAC
CAATGAAATA GCCATGGTCC AGGCCCGTGG TCGAGCCAGA GCTGATGAGA
GCACCTACGT CCTGGTTGCT CACAGTGGTT CAGGAGTTAT CGAACATGAG
ACAGTTAATG ATTTCCGAGA GAAGATGATG TATAAAGCTA TACATTGTGT
TCAAAATATG AAACCAGAGG AGTATGCTCA TAAGATTTTG GAATTACAGA
20 TGCAAAGTAT AATGGAAG AAAATGAAAA CCAAGAGAAA TATTGCCAAG
CATTACAAGA ATAACCCATC ACTAATAACT TTCCTTTGCA AAAACTGCAG
TGTGCTAGCC TGTCTGGGG AAGATATCCA TGTAATTGAG AAAATGCATC
ACGTCAATAT GACCCAGAA TTCAAGGAAC TTTACATTGT AAGAGAAAAAC
AAAGCACTGC AAAAGAAGTG TGCCGACTAT CAAATAAATG GTGAAATCAT
25 CTGCAAATGT GGCCAGGCTT GGGGAACAAT GATGGTGAC AAAGGCTTAG
ATTTGCCTTG TCTCAAAATA AGGAATTTTG TAGTGGTTTT CAAAAATAAT

TCAACAAAGA AACAAATACAA AAAGTGGGTA GAATTACCTA TCACATTTC
CAATCTTGAC TATTCAGAAT GCTGTTTATT TAGTGATGAG GATTAGCACT
TGATTGAAGA TTCTTTTAAA ATACTATCAG TTAAACATTT AATATGATTA
TGATTAATGT ATTCATTATG CTACAGAACT GACATAAGAA TCAATAAAAT
5 GATTGTTTTA CTCTG

MDA-5 potein sequence (SEQ ID NO:2)

MSNGYSTDEN FRYLISCFRA RVKMYIQVEP VLDYLTFLLPA EVKEQIQRTV
ATSGNMQAVE LLLSTLEKGV WHLGWTREFV EALRRTGSPL AARYMNPFLT
10 DLPSPSFENA HDEYLQLLNL LQPTLVDKLL VRDVLDKCME EELLTIEDRN
RIAAAENNGN ESGVRELLKR IVQKENWFSA FLNVLRQTGN NELVQELTGS
DCSESNAEIE NLSQVDGPQV EEQLLSTTVQ PNLEKEVWGM ENNSSSESSFA
DSSVSVSESDT SLAEGSVSCL DESLGHNSNM GSDSGTMGSD SDEENVAARA
SPEPELQLRP YQMEVAQPAL EGKNIIICLP TGSGKTRVAV YIAKDHLDDK
15 KKASEPGKVI VLVNKKVLLVE QLFKKEFQPF LKKWYRVIGL SGDTQLKISF
PEVVKSCDII ISTAQILENS LLNLENGEDA GVQLSDFSLL IIDECHHTNK
EAVYNNIMRH YLMQKLKNR LKKENKPVIP LPQILGLTAS PGVGGAATKQA
KABEHILKLC ANLDAFTIKT VKENLDQLKN QIQEPCKKFA IADATREDPF
KEKLLEIMTR IQTYCQMSPM SDFGTQPYEQ WAIQMEKKAA KKGNRKERV
20 AEHLRKYNEA LQINDTIRMI DAYTHLETFY NEEKDKKFAV IEDDSDEGGD
DEYCDGDEDE DDLKKPLKLD ETDRFLMTLF FENNKMLKRL AENPEYENEK
LTKLRNTIME QYTRTEESAR GIIFTKTRQS AYALSQWITE NEKFAEVGVK
AHLIGAGHS SEFKPMTQNE QKEVISKFRT GKNLLIATV VAEGLDIKE
CNIVIRYGLV TNEIAMVQAR GRARADESTY VLVAHSGSGV IEHETVNDFR
25 EKMMYKAIHC VQNMKPEEYA HKILELQMQS IMEKKMKTKR NIAKHYYKNNP

SLITFLCKNC SVLACSGEDI HVIEKMHHVN MTPEFKELYI VRENKALQKK
CADYQINGEI ICKCGQAWGT MMVHKGLDLP CLKIRNFVVV FKNNSTKKQY
KKWVELPITF PNLDYSECCL FSDED•

5 Mda-5 promoter sequence (SEO ID NO:3)

GCACATTTTG GCCTACAAAG GACCTTATTG TTAAGGCAGA ACCTGCTGGG

AAAACAAAAT ATCCGCCGGA GGAGCTTTGT AGAGCGTTGG TCTTGGTGTC

10

AGAGAGAATT CGCTTTCCTT TTCTGTTTCC CGCGGTGTCC TTAACCAAAG

15

GCCTCCTCTC TTCACCCGCC CCGACCAAAA GGTGGCGTCT CCCTGAGGAA

ACTCCCTCCC CGCCAGGCAG ATTACGTTTA CAAAGTCCTG AGAAGAGAAT

20

CGAAACAGAA ACCAAAGTCA GGCAAACTCT GTAAGAACTG CCTGACAGAA

AGCTGGACTC AAAGCTCCTA CCCGAGTGTG CAGCAGGATC GCCCCGGTCC

25

GGGACCCAG GCGCACACCG CAGAGTCCAA AGTGCCGCGC CTGCCGGCCG

5 CACCTGCCTG CCGCGGCCCC GCGCGCCGCC CCGTGCCCA CCTGCCGCGC

TGCCACCTG CCCAGGTGCG AGTGACAGCC CGCGCGCCGG CCTGAGAGCC

10

CTGTGGACAA CCTCGTCATT GTCAGGCACA GAGCGGTAGA CCCTGCTTCT

NTAAGTGGGC AGCGGACAGC GGCACGCACA TTTCACCTGT CCCGCAGACA

15

ACAGCACCAT CTGCTTGGGA GAACCTCTC CCTTCTCTGA GAAAGAAAGA

20

TGTCGAATGG GTATTCCACA GACGAGAATT TCCGCTATCT CATCTCGTGC

TTCAGGGCCA GGGTGAAAAT GTACATCCAG GTGGAGCCTG TGCTGGACTA

25

CCTGACCTTT CTGCCTGCAG AGGTGAAGGA GCAGATTCAG AGGACAGTCG

CCACCTCCGG GAACATGCAG GCAGTTGAAC TGCTGCTGAG CACCTTGGAG

5

AAGGGAGTCT GGCACCTTGG TTGGA CTGG GAATTCGTGG AGGCCCTCCG

GAGAACCGGC AGCCCTCTGG CCGCCCGCTA CATGAACCTT GAGCTCACGG

10

ACTTGCCCTC TCCATCGTTT GAGAACGCTC ATGATGAATA TCTCCAACTG

15

CTGAACCTCC TTCAGCCAC TCTGGTGGAC AAGCTT

(See also Figure 10 for the Mda-5 promoter sequence).

As used herein "enhancer element" is a nucleotide sequence that increases the rate of transcription of the therapeutic genes or genes of interest but does not have promoter activity. An enhancer can be moved upstream, downstream, and to the other side of a promoter without significant loss of activity.

20

Two DNA or polypeptide sequences are "substantially homologous" when at least about 80% (preferably at least about 90%, and most preferably at least about 95%) of the nucleotides or amino acids match over a defined length of the molecule. As used herein, "substantially homologous" also refers to sequences showing identity to the specified DNA or polypeptide sequence. DNA sequences that

25

are substantially homologous can be identified in a Southern hybridization, experiment under, for example, stringent conditions, as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g.,
5 Sambrook et al., supra; DNA Cloning, vols I & II, supra; Nucleic Acid Hybridization, supra.

A sequence "functionally equivalent" to a *Mda-5* promoter sequence is one which functions in the same manner as the *Mda-5* promoter sequence. Thus, a promoter sequence "functionally equivalent" to
10 the *Mda-5* promoter described herein is one which is capable of directing transcription of a downstream coding sequence in substantially similar timeframes of expression and in substantially similar amounts and with substantially similar tissue specificity as the *Mda-5* promoter.

15 In general terms, an "analog" is understood to be a functional equivalent of a given substance and can be a substitute for said substance, including as a therapeutic substitute. An analog also can be a structural equivalent. As used herein, a "Mda-5 analog" is a substance that mimics a biological effect induced and/or mediated
20 by Mda-5. Any substance having such mimetic properties, regardless of the chemical or biochemical nature thereof, can be used as a Mda-5 analog herein. As used herein, an Mda-5 analog can be referred to as a "mimic" or a "mimetic".

25 A DNA "coding sequence" or a "nucleotide sequence encoding" a particular protein, is a DNA sequence which is transcribed and translated into a polypeptide *in vivo* or *in vitro* when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5'-
30 (amino) terminus and a translation stop codon at the 3'-(carboxy) terminus. A coding sequence can include, but is not limited to, procaryotic sequences, cDNA from eucaryotic mRNA, genomic DNA

sequences from eucaryotic (e.g., mammalian) sources, viral RNA or DNA, and even synthetic nucleotide sequences. A transcription termination sequence will usually be located 3' to the coding sequence.

5

DNA "control sequences" refers collectively to promoter sequences, polyadenylation signals, transcription termination sequences, upstream regulatory domains, enhancers, and the like, untranslated regions, including 5'-UTRs and 3'-UTRs, which collectively provide for the transcription and translation of a coding sequence in a host cell.

10

15

"Operably linked" refers to an arrangement of nucleotide sequence elements wherein the components so described are configured so as to perform their usual function. Thus, control sequences operably linked to a coding sequence are capable of effecting the expression of the coding sequence. The control sequences need not be contiguous with the coding sequence, so long as they function to direct the expression thereof. Thus, for example, intervening untranslated yet transcribed sequences can be present between a promoter sequence and the coding sequence and the promoter sequence can still be considered "operably linked" to the coding sequence.

20

25

A control sequence "directs the transcription" of a coding sequence in a cell when RNA polymerase will bind the promoter sequence and transcribe the coding sequence into mRNA, which is then translated into the polypeptide encoded by the coding sequence.

30

35

A cell has been "transformed" by exogenous DNA when such exogenous DNA has been introduced inside the cell membrane. Exogenous DNA may or may not be integrated (covalently linked) into chromosomal DNA making up the genome of the cell. In procaryotes and yeasts, for example, the exogenous DNA may be maintained on an episomal element, such as a plasmid. In eucaryotic cells, a stably transformed cell is generally one in which the exogenous DNA has

become integrated into the chromosome so that it is inherited by daughter cells through chromosome replication, or one which includes stably maintained extrachromosomal plasmids. This stability is demonstrated by the ability of the eucaryotic cell to establish cell lines or clones comprised of a population of daughter cells containing the exogenous DNA.

A "heterologous" region of a DNA construct is an identifiable segment of DNA within or attached to another DNA molecule that is not found in association with the other molecule in nature. For example, a sequence encoding a protein other than an *Mda-5* is considered a heterologous sequence when linked to an *Mda-5* promoter. Similarly, a sequence encoding an *Mda* gene (i.e., *Mda-6*, *Mda-7*) will be considered heterologous when linked to an *Mda* gene promoter with which it is not normally associated. Another example of a heterologous coding sequence is a construct where the coding sequence itself is not found in nature (e.g., synthetic sequences having codons different from the native gene). Likewise, a chimeric sequence, comprising a heterologous structural gene and a gene encoding an *Mda* or a portion of an *Mda*, linked to an *Mda* promoter, whether derived from the same or a different *Mda* gene, will be considered heterologous since such chimeric constructs are not normally found in nature. Allelic variation or naturally occurring mutational events do not give rise to a heterologous region of DNA, as used herein.

Vectors

Especially preferred are virus based vectors. In the case of eukaryotic cells, retrovirus or adenovirus based vectors are preferred. Such vectors contain all or a part of a viral genome, such as long term repeats ("LTRs"), promoters (e.g., CMV promoters, SV40 promoter, RSV promoter), enhancers, and so forth. When the host cell is a prokaryote, bacterial viruses, or phages, are

preferred. Exemplary of such vectors are vectors based upon, e.g., lambda phage. In any case, the vector may comprise elements of more than one virus.

5 The resulting vectors are transfected or transformed into a host cell, which may be eukaryotic or prokaryotic.

The gene transfer vector of the present invention may additionally comprise a gene encoding a marker or reporter molecule to more
10 easily trace expression of the vector.

Examples of such reporter molecules which can be employed in the present invention are well-known in the art and include beta-galactosidase (Fowler et al, Proc. Natl. Acad. Sci., USA, 74:1507
15 (1977)), luciferase (Tu et al, Biochem., 14:1970 (1975)), and chloramphenicol acetyltransferase (Gorman et al, Mol. Cell Biol., 2:1044-1051 (1982)).

The gene transfer vector may contain more than one gene encoding the same or different foreign polypeptides or RNAs.

20 The gene transfer vector may be any construct which is able to replicate within a host cell and includes plasmids, DNA viruses, retroviruses, as well as isolated nucleotide molecules. Liposome-mediated transfer of the gene transfer vector may also be carried
25 out in the present invention.

Examples of such plasmids which can be employed in the present invention include pGL3-based plasmids (Promega). An example of such DNA viruses which can be employed in the present invention are
30 adenoviruses.

Adenoviruses have attracted increasing attention as expression vectors, especially for human gene therapy (Berkner, Curr. Top.

Microbiol. Immunol., 158:39-66 (1992)).

Examples of such adenovirus serotypes which can be employed in the present invention are well-known in the art and include more than 40 different human adenoviruses, e.g., Ad12 (subgenus A), Ad3 and Ad7 (Subgenus B), Ad2 and Ad5 (Subgenus C), Ad8 (Subgenus D), Ad4 (Subgenus E), Ad40 (Subgenus F) (Wigand et al, In: Adenovirus DNA, Doerfler, Ed., Martinus Nijhoff Publishing, Boston, pp. 408-441 (1986)). Ad5 of subgroup C is the preferred adenovirus employed in the present invention. This is because Ad5 is a human adenovirus about which a great deal of biochemical and genetic information is known, and it has historically been used for most constructions employing adenovirus as a vector. Also, adenoviral vectors are commercially available, e.g., pCA3 (Microbix Biosystems Inc.).

Methods for producing adenovirus vectors are well-known in the art (Berkner et al, Nucleic Acids Res., 11:6003-6020 (1983); van Doren et al, Mol. Cell. Biol., 4:1653-1656 (1984); Ghosh-Choudhury et al, Biochem. Biophys. Res. Commun., 147:964-973 (1987); McGrory et al, Virol., 163:614-617 (1988); and Gluzman et al, In: Eukaryotic Viral Vectors, Ed. Gluzman, Y. pages 187-192, Cold Spring Harbor Laboratory (1982)).

Functionally Equivalent

Nucleic acid molecules which are "functionally equivalent" to *Mda-5* promoter or *Mda-5* cDNA retain the functional properties of the *Mda-5* cDNA or *MDA-5* promoter. The nucleic acid molecule may be a derivative of the *Mda-5* cDNA or promoter such that there are substitutions, deletions, insertions or alterations in the nucleotide sequence which do not alter substantially the function of the nucleic acid. For example, a promoter molecule which is a functional equivalent of *Mda-5* promoter having such substitutions will still permit the tissue specific expression of a gene of interest operably linked thereto and expressed in an organism.

Modification is permitted so long as the derivative molecules retain its increased potency compared to *Mda-5* promoter alone and its tissue specificity. A functional equivalent of *Mda-5* cDNA will encode a protein which retains substantially the same biological functions which are characteristic of *Mda-5*.

The promoter of the present invention in one embodiment is operably linked to a gene of interest. Such a gene of interest is preferably a therapeutic gene. Examples of therapeutic genes include suicide genes, envisioned for the treatment of cancer, for example. These are genes sequences the expression of which produces a protein or agent that inhibits tumor cell growth or induces tumor cell death. Suicide genes include genes encoding enzymes, oncogenes, tumor suppressor genes, genes encoding toxins, genes encoding cytokines, or a gene encoding oncostatin. The purpose of the therapeutic gene is to inhibit the growth of or kill cancer cells or produce cytokines or other cytotoxic agents which directly or indirectly inhibit the growth of or kill the cancer cell.

Suitable enzymes include thymidine kinase (TK), xanthine-guanine phosphoribosyltransferase (GPT) gene from *E. coli* or *E. coli* cytosine deaminase (CD), or hypoxanthine phosphoribosyl transferase (HPRT).

Suitable oncogenes and tumor suppressor genes include *neu*, *EGF*, *ras* (including *H*, *K*, and *N ras*), *p53*, *Retinoblastoma* tumor suppressor gene (*Rb*), *Wilm's Tumor Gene Product*, *Phosphotyrosine Phosphatase* (PTPase), and *nm23*. Suitable toxins include *Pseudomonas* exotoxin *A* and *S*; *diphtheria* toxin (DT); *E. coli* LT toxins, *Shiga* toxin, *Shiga-like* toxins (SLT-1, -2), *ricin*, *abrin*, *supporin*, and *gelonin*.

In one embodiment, the gene of interest is a cytokine. Suitable cytokines include *interferons*, *GM-CSF* *interleukins*, *tumor necrosis*

factor (TNF) (Wong G, et al., Human GM-CSF: Molecular cloning of the complementary DNA and purification of the natural and recombinant proteins. *Science* 1985; 228:810); WO9323034 (1993); Horisberger M. A., et al., Cloning and sequence analyses of cDNAs for interferon-beta and virus-induced human Mx proteins reveal that they contain putative guanine nucleotide-binding sites: functional study of the corresponding gene promoter. *Journal of Virology*, 1990 Mar, 64(3):1171-81; Li YP et al., Proinflammatory cytokines tumor necrosis factor-alpha and IL-6, but not IL-1, down-regulate the osteocalcin gene promoter. *Journal of Immunology*, Feb. 1, 1992, 148(3):788-94; Pizarro T. T., et al. Induction of TNF alpha and TNF beta gene expression in rat cardiac transplants during allograft rejection. *Transplantation*, 1993 Aug., 56(2):399-404). (Breviario F., et al., Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. *Journal of Biological Chemistry*, Nov. 5, 1992, 267(31):22190-7; Espinoza-Delgado I., et al., Regulation of IL-2 receptor subunit genes in human monocytes. Differential effects of IL-2 and IFN-gamma. *Journal of Immunology*, Nov. 1, 1992, 149(9):2961-8; Algate P. A., et al., Regulation of the interleukin-3 (IL-3) receptor by IL-3 in the fetal liver-derived FL5.12 cell line. *Blood*, 1994 May 1, 83(9):2459-68; Cluitmans F. H., et al., IL-4 down-regulates IL-2-, IL-3-, and GM-CSF-induced cytokine gene expression in peripheral blood monocytes. *Annals of Hematology*, 1994 Jun., 68(6):293-8; Lagoo, A. S., et al., IL-2, IL-4, and IFN-gamma gene expression versus secretion in superantigen-activated T cells. Distinct requirement for costimulatory signals through adhesion molecules. *Journal of Immunology*, Feb. 15, 1994, 152(4):1641-52; Martinez O. M., et al., IL-2 and IL-5 gene expression in response to alloantigen in liver allograft recipients and in vitro. *Transplantation*, 1993 May, 55(5):1159-66; Pang G, et al., GM-CSF, IL-1 alpha, IL-1 beta, IL-6, IL-8, IL-10, ICAM-1 and VCAM-1 gene expression and cytokine production in human duodenal fibroblasts stimulated with lipopolysaccharide, IL-1 alpha and TNF-alpha. *Clinical and Experimental Immunology*, 1994 Jun., 96(3):437-

43; Ulich T. R., et al., Endotoxin-induced cytokine gene expression in vivo. III. IL-6 mRNA and serum protein expression and the in vivo hematologic effects of IL-6. *Journal of Immunology*, Apr. 1, 1991, 146(7):2316-23; Mauviel A., et al., Leukoregulin, a T cell-derived cytokine, induces IL-8 gene expression and secretion in human skin fibroblasts. Demonstration and secretion in human skin fibroblasts. Demonstration of enhanced NF-kappa B binding and NF-kappa B-driven promoter activity. *Journal of Immunology*, Nov. 1, 1992, 149(9):2969-76).

The gene of interest is a growth factor in one embodiment. Growth factors include Transforming Growth Factor-alpha (TGF-alpha) and beta (TGF-beta), cytokine colony stimulating factors (Shimane M., et al., Molecular cloning and characterization of G-CSF induced gene cDNA. *Biochemical and Biophysical Research Communications*, Feb. 28, 1994, 199(1):26-32; Kay A. B., et al., Messenger RNA expression of the cytokine gene cluster, interleukin 3 (IL-3), IL-4, IL-5, and granulocyte/macrophage colony-stimulating factor, in allergen-induced late-phase cutaneous reactions in atopic subjects. *Journal of Experimental Medicine*, Mar. 1, 1991, 173(3):775-8; de Wit H, et al., Differential regulation of M-CSF and IL-6 gene expression in monocytic cells. *British Journal of Haematology*, 1994 Feb., 86(2):259-64; Sprecher E., et al., Detection of IL-1 beta, TNF-alpha, and IL-6 gene transcription by the polymerase chain reaction in keratinocytes, Langerhans cells and peritoneal exudate cells during infection with herpes simplex virus-1. *Archives of Virology*, 1992, 126(1-4):253-69).

Preferred vectors for use in the methods of the present invention are viral including adenoviruses, retroviral, vectors, adeno-associated viral (AAV) vectors.

The viral vector selected should meet the following criteria: 1) the vector must be able to infect the tumor cells and thus viral vectors having an appropriate host range must be selected; 2) the

transferred gene should be capable of persisting and being expressed in a cell for an extended period of time; and 3) the vector should be safe to the host and cause minimal cell transformation. Retroviral vectors and adenoviruses offer an efficient, useful, and presently the best-characterized means of introducing and expressing foreign genes efficiently in mammalian cells. These vectors have very broad host and cell type ranges, express genes stably and efficiently. The safety of these vectors has been proved by many research groups. In fact many are in clinical trials.

Other virus vectors that may be used for gene transfer into cells for correction of disorders include retroviruses such as Moloney murine leukemia virus (MoMuLV); papovaviruses such as JC, SV40, polyoma, adenoviruses; Epstein-Barr Virus (EBV); papilloma viruses, e.g. bovine papilloma virus type I (BPV); vaccinia and poliovirus and other human and animal viruses.

Adenoviruses have several properties that make them attractive as cloning vehicles (Bachettis et al.: Transfer of gene for thymidine kinase-deficient human cells by purified herpes simplex viral DNA. PNAS USA, 1977 74:1590; Berkner, K. L.: Development of adenovirus vectors for expression of heterologous genes. Biotechniques, 1988 6:616; Ghosh-Choudhury G., et al., Human adenovirus cloning vectors based on infectious bacterial plasmids. Gene 1986; 50:161; Hag-Ahmand Y., et al., Development of a helper-independent human adenovirus vector and its use in the transfer of the herpes simplex virus thymidine kinase gene. J Virol 1986; 57:257; Rosenfeld M., et al., Adenovirus-mediated transfer of a recombinant .alpha..sub.1 - antitrypsin gene to the lung epithelium in vivo. Science 1991; 252:431).

For example, adenoviruses possess an intermediate sized genome that replicates in cellular nuclei; many serotypes are clinically innocuous; adenovirus genomes appear to be stable despite insertion

of foreign genes; foreign genes appear to be maintained without loss or rearrangement; and adenoviruses can be used as high level transient expression vectors with an expression period up to 4 weeks to several months. Extensive biochemical and genetic studies suggest that it is possible to substitute up to 7-7.5 kb of heterologous sequences for native adenovirus sequences generating viable, conditional, helper-independent vectors (Kaufman R. J.; identification of the component necessary for adenovirus translational control and their utilization in cDNA expression vectors. PNAS USA, 1985 82:689).

AAV is a small human parvovirus with a single stranded DNA genome of approximately 5 kb. This virus can be propagated as an integrated provirus in several human cell types. AAV vectors have several advantage for human gene therapy. For example, they are trophic for human cells but can also infect other mammalian cells; (2) no disease has been associated with AAV in humans or other animals; (3) integrated AAV genomes appear stable in their host cells; (4) there is no evidence that integration of AAV alters expression of host genes or promoters or promotes their rearrangement; (5) introduced genes can be rescued from the host cell by infection with a helper virus such as adenovirus.

HSV-1 vector system facilitates introduction of virtually any gene into non-mitotic cells (Geller et al. an efficient deletion mutant packaging system for a defective herpes simplex virus vectors: Potential applications to human gene therapy and neuronal physiology. PNAS USA, 1990 87:8950).

Another vector for mammalian gene transfer is the bovine papilloma virus-based vector (Sarver N, et al., Bovine papilloma virus DNA: A novel eukaryotic cloning vector. Mol Cell Biol 1981; 1:486). Vaccinia and other poxvirus-based vectors provide a mammalian gene transfer system. Vaccinia virus is a large double-stranded DNA virus of 120 kilodaltons (kd) genomic size (Panicali D, et al.,

Construction of poxvirus as cloning vectors: Insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci USA 1982; 79:4927; Smith et al. infectious vaccinia virus recombinants that express hepatitis B virus surface antigens. Nature, 1983 302:490.)

Retroviruses are packages designed to insert viral genes into host cells (Guild B, et al., Development of retrovirus vectors useful for expressing genes in cultured murine embryonic cells and hematopoietic cells in vivo. J Virol 1988; 62:795; Hock R. A., et al., Retrovirus mediated transfer and expression of drug resistance genes in human hemopoietic progenitor cells. Nature 1986; 320:275).

The basic retrovirus consists of two identical strands of RNA packaged in a proviral protein. The core surrounded by a protective coat called the envelope, which is derived from the membrane of the previous host but modified with glycoproteins contributed by the virus.

Markers and amplifiers can also be employed in the gene transfer vectors of the invention. A variety of markers are known which are useful in selecting for transformed cell lines and generally comprise a gene whose expression confers a selectable phenotype on transformed cells when the cells are grown in an appropriate selective medium. Such markers for mammalian cell lines include, for example, the bacterial xanthine-guanine phosphoribosyl transferase gene, which can be selected for in medium containing mycophenolic acid and xanthine (Mulligan et al. (1981) Proc. Natl. Acad. Sci. USA 78:2072-2076), and the aminoglycoside phosphotransferase gene (specifying a protein that inactivates the antibacterial action of neomycin/kanamycin derivatives), which can be selected for using medium containing neomycin derivatives such as G418 which are normally toxic to mammalian cells (Colbere-Garapin et al. (1981) J. Mol. Biol. 150:1-14). Useful markers for other eucaryotic expression systems, are well known to those of

skill in the art.

Infection of cells can be carried out *in vitro* or *in vivo*. *In vitro* infection of cells is performed by adding the gene transfer vectors to the cell culture medium. When infection is carried out *in vivo*, the solution containing the gene transfer vectors may be administered by a variety of modes, depending on the tissue which is to be infected. Examples of such modes of administration include injection of gene transfer vectors into the skin, topical application onto the skin, direct application to a surface of epithelium, or instillation into an organ (e.g., time release patch or capsule below the skin or into a tumor), oral administration, injection into the cerebro-spinal fluid, intranasal application, application into eye by dropper, etc.

Expression can be amplified by placing an amplifiable gene, such as the mouse dihydrofolate reductase (*dhfr*) gene adjacent to the coding sequence. Cells can then be selected for methotrexate resistance in *dhfr*-deficient cells. See, e.g. Urlaub et al. (1980) Proc. Natl. Acad. Sci. USA 77:4216-4220; Rungold et al. (1981) J. Mol. and Appl. Genet. 1:165-175.

The above-described system can be used to direct the expression of a wide variety of procaryotic, eucaryotic and viral proteins, (genes of interest) including, for example, viral glycoproteins suitable for use as vaccine antigens, immunomodulators for regulation of the immune response, hormones, cytokines and growth factors, as well as proteins useful in the production of other biopharmaceuticals.

It may also be desirable to produce mutants or analogs of the proteins of interest. See description of "functionally equivalent" nucleic acids hereinabove. Such mutants or analogs of the proteins of interest in one embodiment are expressed from functionally equivalent nucleic acids of the gene of interest or of Mda-5 cDNA.

Mutants or analogs may be prepared by the deletion of a portion of the sequence encoding the protein, by insertion of a sequence, and/or by substitution of one or more nucleotides within the sequence. Techniques for modifying nucleotide sequences, such as site-directed mutagenesis, are well known to those skilled in the art. See, e.g., Sambrook et al., supra; DNA Cloning, Vols. I and II, supra; Nucleic Acid Hybridization, supra.

For purposes of the present invention, it may be desirable to further engineer the coding sequence to effect secretion of the polypeptide from the host organism. This enhances clone stability and prevents the toxic build up of proteins in the host cell so that expression can proceed more efficiently. Homologous signal sequences can be used for this purpose with proteins normally found in association with a signal sequence. Additionally, heterologous leader sequences which provide for secretion of the protein can be added to the constructs. Preferably, processing sites will be included such that the leader fragment can be cleaved from the protein expressed therewith. (See, e.g., U.S. Pat. No. 4,336,246 for a discussion of how such cleavage sites can be introduced). The leader sequence fragment typically encodes a signal peptide comprised of hydrophobic amino acids.

In one embodiment of the invention, a heterologous gene sequence, i.e., a therapeutic gene, is inserted into the nucleic acid molecule of the invention. Other embodiments of the isolated nucleic acid molecule of the invention include the addition of a single enhancer element or multiple enhancer elements which amplify the expression of the heterologous therapeutic gene without compromising tissue specificity.

The transformation procedure used depends upon the host to be transformed. Mammalian cells can conveniently be transformed using, for example, DEAE-dextran based procedures, calcium phosphate precipitation (Graham, F. L. and Van der Eb, A. J. (1973) Virology

52:456-467), protoplast fusion, liposome-mediated transfer, polybrene-mediated transfection and direct microinjection of the DNA into nuclei. Bacterial cells will generally be transformed using calcium chloride, either alone or in combination with other divalent cations and DMSO (Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition (1989)). DNA can also be introduced into bacterial cells by electroporation. Methods of introducing exogenous DNA into yeast hosts typically include either the transformation of spheroplasts or transformation of intact yeast cells treated with alkali cations.

The constructs can also be used in gene therapy or nucleic acid immunization, to direct the production of the desired gene product in vivo, by administering the expression constructs directly to a subject for the in vivo translation thereof. See, e.g. EPA Publication No. 336,523 (Dreano et al., published Oct. 11, 1989). Alternatively, gene transfer can be accomplished by transfecting the subject's cells or tissues with the expression constructs ex vivo and reintroducing the transformed material into the host. The constructs can be directly introduced into the host organism, i.e., by injection (see International Publication No. WO/90/11092; and Wolff et al., (1990) Science 247:1465-1468). Liposome-mediated gene transfer can also be accomplished using known methods. See, e.g., Hazinski et al., (1991) Am. J. Respir. Cell Mol. Biol. 4:206-209; Brigham et al. (1989) Am. J. Med. Sci. 298:278-281; Canonico et al. (1991) Clin. Res. 39:219A; and Nabel et al. (1990) Science 249:1285-1288. Targeting agents, such as antibodies directed against surface antigens expressed on specific cell types, can be covalently conjugated to the liposomal surface so that the nucleic acid can be delivered to specific tissues and cells for local administration.

Human Gene Therapy and Diagnostic Use of Vector

There are several protocols for human gene therapy which have been approved for use by the Recombinant DNA Advisory Committee (RAC)

which conform to a general protocol of target cell infection and administration of transfected cells (see for example, Blaese, R.M., et al., 1990; Anderson, W. F., 1992; Culver, K.W. et al., 1991). In addition, U.S. Patent No. 5,399,346 (Anderson, W. F. et al., March 21, 1995, U.S. Serial No. 220,175) describes procedures for retroviral gene transfer. The contents of these support references are incorporated in their entirety into the subject application. Retroviral-mediated gene transfer requires target cells which are undergoing cell division in order to achieve stable integration hence, cells are collected from a subject often by removing blood or bone marrow. It may be necessary to select for a particular subpopulation of the originally harvested cells for use in the infection protocol. Then, a retroviral vector containing the gene(s) of interest would be mixed into the culture medium. The vector binds to the surface of the subject's cells, enters the cells and inserts the gene of interest randomly into a chromosome. The gene of interest is now stably integrated and will remain in place and be passed to all of the daughter cells as the cells grow in number. The cells may be expanded in culture for a total of 9-10 days before reinfusion (Culver et al., 1991). As the length of time the target cells are left in culture increases, the possibility of contamination also increases, therefore a shorter protocol would be more beneficial. This invention provides for the construction of retrovirus vectors containing the Mda-5 cDNA in a replicable gene transfer vector or Mda-5 promoter linked to a gene of interest for use in gene therapy or for diagnostic uses. The efficiency of transduction of these vectors can be tested in cell culture systems.

Uses of the Compositions of the Invention

This invention involves targeting a gene-of-interest to the a cancer cell so that the protein encoded by the gene is expressed and directly or indirectly ameliorate the diseased state.

After infecting a susceptible cell, the transgene driven by a specific promoter in the vector expresses the protein encoded by the gene. The use of the highly specific gene vector will allow selective expression of the specific genes in cancer cells.

5 In one embodiment, the present invention relates to a process for administering modified vectors into the skin to treat skin cancer or disorders associated with the skin. More particularly, the invention relates to the use of vectors carrying functional
10 therapeutic genes to produce molecules that are capable of directly or indirectly affecting cells in the skin to repair damage sustained by the cells from defects, disease or trauma.

15 Preferably, for treating cancer or for treating defects, disease or damage of cells in the skin, vectors of the invention include a therapeutic gene or transgenes, for example a gene encoding TK. The genetically modified vectors are administered into the skin to treat defects, disease such as skin cancer by introducing a therapeutic gene product or products into the skin that enhance the
20 production of endogenous molecules that have ameliorative effects in vivo.

The basic tasks in the present method of the invention are
25 isolating the gene of interest, selecting the proper vector vehicle to deliver the gene of interest to the body, administering the vector having the gene of interest into the body, and achieving appropriate expression of the gene of interest. The present invention provides packaging the cloned genes, i.e. the genes of
30 interest, in such a way that they can be injected directly into the bloodstream or relevant organs of patients who need them. The packaging will protect the foreign DNA from elimination by the immune system and direct it to appropriate tissues or cells.

35 In one embodiment of the invention, the gene of interest (desired coding sequence) is a tumor suppressor gene. The tumor suppressor

gene may be p21, RB (retinoblastoma) or p53. One of skill in the art would know of other tumor suppressor genes. Recent U.S. Patent Nos. 6,025,127 and 5,912,236 are hereby incorporated by reference to more explicitly describe the state of the art as to tumor suppressor genes.

Along with the human or animal gene of interest another gene, e.g., a selectable marker, can be inserted that will allow easy identification of cells that have incorporated the modified retrovirus. The critical focus on the process of gene therapy is that the new gene must be expressed in target cells at an appropriate level with a satisfactory duration of expression.

The methods described below to modify vectors and administering such modified vectors into the skin are merely for purposes of illustration and are typical of those that might be used. However, other procedures may also be employed, as is understood in the art.

Most of the techniques used to construct vectors and the like are widely practiced in the art, and most practitioners are familiar with the standard resource materials which describe specific conditions and procedures. However, for convenience, the following paragraphs may serve as a guideline.

General Methods for Vector Construction

Construction of suitable vectors containing the desired therapeutic gene coding and control sequences employs standard ligation and restriction techniques, which are well understood in the art (see Maniatis et al., in Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York (1982)). Isolated plasmids, DNA sequences, or synthesized oligonucleotides are cleaved, tailored, and religated in the form desired.

Site-specific DNA cleavage is performed by treating with the

suitable restriction enzyme (or enzymes) under conditions which are generally understood in the art, and the particulars of which are specified by the manufacturer of these commercially available restriction enzymes (See, e.g. New England Biolabs Product Catalog). In general, about 1 μ g of plasmid or DNA sequences is cleaved by one unit of enzyme in about 20 μ l of buffer solution. Typically, an excess of restriction enzyme is used to insure complete digestion of the DNA substrate.

Incubation times of about one hour to two hours at about 37 degree. C. are workable, although variations can be tolerated. After each incubation, protein is removed by extraction with phenol/chloroform, and may be followed by ether extraction, and the nucleic acid recovered from aqueous fractions by precipitation with ethanol. If desired, size separation of the cleaved fragments may be performed by polyacrylamide gel or agarose gel electrophoresis using standard techniques. A general description of size separations is found in Methods in Enzymology 65:499-560 (1980). Restriction cleaved fragments may be blunt ended by treating with the large fragment of E. coli DNA polymerase I (Klenow) in the presence of the four deoxynucleotide triphosphates (dNTPs) using incubation times of about 15 to 25 min at 20.degree. C. to 25.degree. C. in 50 mM Tris (pH 7.6) 50 mM NaCl, 6 mM MgCl.sub.2, 6 mM DTT and 5-10 .mu.M dNTPs. The Klenow fragment fills in at 5' sticky ends but chews back protruding 3' single strands, even though the four dNTPs are present. If desired, selective repair can be performed by supplying only one of the dNTPs, or with selected dNTPs, within the limitations dictated by the nature of the sticky ends. After treatment with Klenow, the mixture is extracted with phenol/chloroform and ethanol precipitated. Treatment under appropriate conditions with S1 nuclease or Bal-31 results in hydrolysis of any single-stranded portion.

Ligations are performed in 10-50 μ l volumes under the following standard conditions and temperatures using T4 DNA ligase. Ligation

protocols are standard (D. Goeddel (ed.) Gene Expression Technology: Methods in Enzymology (1991)). In vector construction employing "vector fragments", the vector fragment is commonly treated with bacterial alkaline phosphatase (BAP) or calf intestinal alkaline phosphatase (CIP) in order to remove the 5' phosphate and prevent religation of the vector. Alternatively, religation can be prevented in vectors which have been double digested by additional restriction enzyme digestion of the unwanted fragments.

Suitable vectors include viral vector systems e.g. ADV, RV, and AAV (R. J. Kaufman "Vectors used for expression in mammalian cells" in Gene Expression Technology, edited by D. V. Goeddel (1991)).

Many methods for inserting functional DNA transgenes into cells are known in the art. For example, non-vector methods include nonviral physical transfection of DNA into cells; for example, microinjection (DePamphilis et al., BioTechnique 6:662-680 (1988)); liposomal mediated transfection (Felgner et al., Proc. Natl. Acad. Sci. USA, 84:7413-7417 (1987), Felgner and Holm, Focus 11:21-25 (1989) and Felgner et al., Proc. West. Pharmacol. Soc. 32: 115-121 (1989)) and other methods known in the art.

Administration of Modified Vectors Into Subject

One way to get DNA into a target cell is to put it inside a membrane bound sac or vesicle such as a spheroplast or liposome, or by calcium phosphate precipitation (CaPO.sub.4) (Graham F. and Van der Eb, A., Virology 52:456 1973; Schaefer-Ridder M., et al., Liposomes as gene carriers: Efficient transduction of mouse L cells by thymidine kinase gene. Science 1982; 215:166; Stavridis J. C., et al., Construction of transferrin-coated liposomes for in vivo transport of exogenous DNA to bone marrow erythroblasts in rabbits. Exp Cell Res 1986; 164:568-572).

A vesicle can be constructed in such a way that its membrane will

fuse with the outer membrane of a target cell. The vector of the invention in vesicles can home into the cancer cells.

The spheroplasts are maintained in high ionic strength buffer until they can be fused through the mammalian target cell using fusogens such as polyethylene glycol.

Liposomes are artificial phospholipid vesicles. Vesicles range in size from 0.2 to 4.0 micrometers and can entrap 10% to 40% of an aqueous buffer containing macromolecules. The liposomes protect the DNA from nucleases and facilitate its introduction into target cells. Transfection can also occur through electroporation.

Before administration, the modified vectors are suspended in complete PBS at a selected density for injection. In addition to PBS, any osmotically balanced solution which is physiologically compatible with the subject may be used to suspend and inject the modified vectors into the host.

For injection, the cell suspension is drawn up into the syringe and administered to anesthetized recipients. Multiple injections may be made using this procedure. The viral suspension procedure thus permits administration of genetically modified vectors to any predetermined site in the skin, is relatively non-traumatic, allows multiple administrations simultaneously in several different sites or the same site using the same viral suspension. Multiple injections may consist of a mixture of therapeutic genes.

Survival of the Modified Vectors So Administered

Expression of a gene is controlled at the transcription, translation or post-translation levels. Transcription initiation is an early and critical event in gene expression. This depends on the promoter and enhancer sequences and is influenced by specific cellular factors that interact with these sequences. The transcriptional unit of many prokaryotic genes consists of the promoter and in some cases enhancer or regulator elements (Banerji

et al., Cell 27:299 (1981); Corden et al., Science 209:1406 (1980); and Breathnach and Chambon, Ann. Rev. Biochem. 50:349 (1981)).

For retroviruses, control elements involved in the replication of the retroviral genome reside in the long terminal repeat (LTR) (Weiss et al., eds., In: The molecular biology of tumor viruses: RNA tumor viruses, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1982)).

Moloney murine leukemia virus (MLV) and Rous sarcoma virus (RSV) LTRs contain promoter and enhancer sequences (Jolly et al., Nucleic Acids Res. 11:1855 (1983); Capecchi et al., In: Enhancer and eukaryotic gene expression, Gulzman and Shenk, eds., pp. 101-102, Cold Spring Harbor Laboratories, Cold Spring Harbor, N.Y.).

Promoter and enhancer regions of a number of non-viral promoters have also been described (Schmidt et al., Nature 314:285 (1985); Rossi and de Crombrughe, Proc. Natl. Acad. Sci. USA 84:5590-5594 (1987)).

The present invention provides methods for maintaining and increasing expression of therapeutic genes using a tissue specific promoter.

In addition to using viral and non-viral promoters to drive therapeutic gene expression, an enhancer sequence may be used to increase the level of therapeutic gene expression. Enhancers can increase the transcriptional activity not only of their native gene but also of some foreign genes (Armstrong, Proc. Natl. Acad. Sci. USA 70:2702 (1973)).

For example, in the present invention, CMV enhancer sequences are used with the Mda-5 promoter to increase therapeutic gene expression. Therapeutic gene expression may also be increased for long term stable expression after injection using cytokines to modulate promoter activity.

The methods of the invention are exemplified by preferred embodiments in which modified vectors carrying a therapeutic gene are injected intracerebrally into a subject.

The most effective mode of administration and dosage regimen for the molecules of the present invention depends upon the exact location of the melanoma being treated, the severity and course of the cancer, the subject's health and response to treatment and the judgment of the treating physician. Accordingly, the dosages of the molecules should be titrated to the individual subject. The molecules may be delivered directly or indirectly via another cell, autologous cells are preferred, but heterologous cells are encompassed within the scope of the invention.

The interrelationship of dosages for animals of various sizes and species and humans based on mg/m^2 of surface area is described by Freireich, E. J., et al. Cancer Chemother., Rep. 50 (4):219-244 (1966). Adjustments in the dosage regimen may be made to optimize the tumor cell growth inhibiting and killing response, e.g., doses may be divided and administered on a daily basis or the dose reduced proportionally depending upon the situation (e.g., several divided dose may be administered daily or proportionally reduced depending on the specific therapeutic situation).

It would be clear that the dose of the molecules of the invention required to achieve cures may be further reduced with schedule optimization.

Advantages of the Invention

The Mda-5 promoter of the invention exhibits melanocyte tissue specificity. Since the Mda-5 promoter of the invention is tissue-specific it can only be activated in the targeted tissue, i.e., the skin. Therefore, the genes of interest driven by the Mda-5 promoter will be differentially expressed in these cells,

minimizing systemic toxicity.

This invention is illustrated in the Experimental Details section which follows. These sections are set forth to aid in an understanding of the invention but are not intended to, and should not be construed to, limit in any way the invention as set forth in the claims which follow thereafter.

5

5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

EXPERIMENTAL DETAILS

Example 1: Melanoma Differentiation Associated Gene-5, Mda-5, A Novel Interferon Inducible Gene with Structural Similarities to RNA Helicases and CARD Motif Containing Proteins

Abstract

Melanoma differentiation associated gene-5, mda-5, is induced during terminal differentiation in human melanoma cells treated with the combination of recombinant fibroblast interferon (IFN-) and the antileukemic compound mezerein (MEZ). The complete open reading frame of the mda-5 cDNA and its promoter region has now been identified and characterized. Mda-5 encodes a 116.7-kDa protein that contains a caspase recruitment domain (CARD) and an RNA helicase motif. Treatment of HO-1 human melanoma and human skin fibroblast cells with IFN- α , IFN- β , IFN- γ , TNF- α and poly IC induce mda-5 expression. IFN- β and poly IC are the most potent single inducers of mda-5 expression, resulting in a ≥ 5 -fold higher induction than with other inducers. Induction of mda-5 expression by IFN- β is also apparent in normal and tumor cell lines of diverse origin. Thus, mda-5 is a novel IFN- β -responsive gene. MEZ, which reversibly induces specific markers of differentiation in HO-1 cells, does not induce mda-5 expression, whereas it increases both the level of steady-state mda-5 mRNA and mda-5 RNA transcription. The finding that most organs, except brain and lung, contain low levels of mda-5 transcripts suggest that the biological role of mda-5 may be closely related to its induction by exogenous agents. Nuclear run-on assays indicate that the level of regulation of mda-5 occurs transcriptionally. The half-life of mda-5 following treatment with IFN- β or IFN- β + MEZ is between 5~6 hr, confirming that the primary regulation of mda-5 by these agents occurs by enhanced RNA transcription rates. Isolation and characterization of the promoter region of mda-5, provides further documentation that the primary mode of regulation of this gene involves changes in RNA

transcription. MDA-5 protein was detected at the predicted size by in vitro translation and Western blot analysis of transiently expressed fusion proteins. GFP-mda-5 fusion proteins were produced and found to localize in the cytoplasm where mda-5 may effects on mRNA translation, mRNA sequestration and decay of specific messages. Ectopic expression of mda-5 reduces the colony-forming efficiency of HO-1 melanoma cells by ~70%, which suggests a growth inhibitory or a pro-apoptotic role of mda-5. In these contexts, mda-5 may play a key role in growth inhibition induced by IFN- β and may also function in apoptotic signaling.

Introduction

Abnormalities in differentiation are common occurrences in human cancers ((1)Fisher and Grant, 1985; (2) Waxman, 1995). Moreover, as cancer cells evolve, ultimately developing new phenotypes or acquiring a further elaboration of preexisting transformation-related properties, the degree of expression of differentiation-associated traits often undergo a further decline. These observations have been exploited as a novel means of cancer therapy in which tumor cells are treated with agents that induce differentiation and a loss of cancerous properties, a strategy called 'differentiation therapy' ((2-4) Waxman et al., 1988, 1991; Jiang et al., 1994; Waxman, 1995). In principle, differentiation therapy may prove less toxic than currently employed chemotherapeutic approaches, including radiation and treatment with toxic chemicals. The ability to develop rational schemes for applying differentiation therapy clinically require appropriate in vitro and in vivo model systems for identifying and characterizing the appropriate agent or agents that can modulate differentiation in cancer cells without causing undue toxicity to normal cells.

Treatment of human melanoma cells with a combination of recombinant human fibroblast interferon (IFN- β) and the antileukemic compound mezerein (MEZ) results in a rapid and irreversible suppression of

growth and the induction of terminal cell differentiation ((5) Fisher et al., 1985). This process is associated with a number of changes in cellular phenotype and gene expression ((3, 6-7) Jiang et al., 1993, Jiang et al., 1994). To define the molecular basis of terminal differentiation in human melanoma cells subtraction hybridization has been employed ((8) Jiang and Fisher, 1993). In brief, cDNA libraries were prepared from temporal RNA samples obtained from HO-1 human melanoma cells treated with IFN- β + MEZ and control untreated HO-1 cells and control cDNAs were subtracted away from differentiation-inducer treated cDNAs ((8) Jiang and Fisher, 1993). This approach resulted in an enrichment of genes displaying elevated expression as a function of treatment with the different inducers and the induction of irreversible growth suppression and terminal cell differentiation. Screening of the subtracted differentiation inducer treated HO-1 cDNA library identified both known and novel cDNAs displaying elevated expression in differentiation inducer treated HO-1 cells ((3, 6, 8-14) Jiang and Fisher, 1993; Jiang et al., 1994, 1995, 1996; Lin et al., 1994, 1996; Huang et al., 1999a, 1999b). Four classes of genes, called melanoma differentiation associated (mda) genes, have been cloned using this approach ((8) Jiang and Fisher, 1993). These include genes displaying elevated expression as a function of treatment with: IFN- β and IFN- β + MEZ (Type I mda genes); MEZ and IFN- β + MEZ (Type II mda genes); IFN- β , MEZ and IFN- β + MEZ (Type III mda genes); and predominantly with IFN- β + MEZ ((3,8) Jiang and Fisher, 1993; Jiang et al., 1994). This approach has resulted in the cloning of both known and novel genes involved in important cellular processes, including cell cycle control (mda-6/p21), interferon signaling (ISG-15, ISG-54), cancer growth control (mda-7), immune interferon response (mda-9), transcription control (c-jun, jun-B), immune recognition (HLA Class I) and cell membrane processes (α 5 integrin, β a integrin, fibronectin) ((3, 8-15) Jiang and Fisher, 1993; Jiang et al., 1994; Jiang et al., 1995a, 1995b, 1996, 1996; Lin et al., 1994, 1996).

Subtraction hybridization initially identified a small EST named mda-5. Expression of mda-5 was elevated in HO-1 cells treated with IFN- β + MEZ and to a lesser extent by IFN β + IFN- γ . A complete mda-5 cDNA has now been cloned and its properties determined. This gene is a novel early IFN responsive gene, whose activity is increased maximally by treatment with IFN- β and dsRNA. Moreover, the combination of IFN- β + MEZ synergistically induces mda-5 expression in HO-1 and additional cell types, both normal and cancer. The protein structure of MDA-5 indicates potential relationships to RNA helicases and genes containing CARD domains. However, based on the structure of the MDA-5 protein this gene may represent a new member of the helicase gene family. Ectopic expression of mda-5 induces growth suppression, as indicated by a reduction in colony formation, in HO-1 human melanoma cells. Identification, cloning and analysis of upstream genomic sequences have confirmed that the mda-5 gene is responsive at a transcriptional to induction primarily by IFN- β and dsRNA. A potential role for mda-5 in growth suppression induced by IFN and as a molecule involved in the cellular defense mechanism against viral infection is suggested.

Materials and Methods

Cell Culture and Treatment Protocol: HO-1 human melanoma cells, early passage human skin fibroblast (purchased from ATCC) and 293T cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum at 37°C in a 5% CO₂/95% air humidified incubator. Prior to treatment, cells were refed with fresh medium and exposed to the indicated compound(s) at the concentrations specified in the figure legends.

Cloning and Sequencing of mda-5: The full length of the mda-5 cDNA was cloned by using the complete open reading frame (C-ORF) technology based on the partial mda-5 EST sequence ((16) Kang and Fisher, 2000). Sequencing was performed by the dye-conjugated

dideoxy chain termination method. The ORF of mda-5 was cloned into the SmaI site of pcDEF3 in which mda-5 expression was regulated by the EF-1 α promoter. Deletion mutant DN7 (D310-484 spanning the ATPase motif) was constructed by ligation of BamHI-StuI fragment with Klenow-filled AlwNI-NotI fragment into pcDEF3. Antisense mda-5 expression vector was constructed by cloning the 1-1830 bp mda-5 cDNA fragment in an antisense orientation into pcDEF3. GFP-mda-5 fusion expression vector was constructed by ligation of the mda-5 cDNA into the SmaI site of pEGFP-C2. The sequences of the expression vectors were verified as described above.

Northern Blot Analyses and Nuclear Run-On Assays: Total cellular RNA samples were prepared by guanidium isothiocyanate/phenol extraction followed by isopropanol precipitation. Ten 10 μ g of total RNA were resolved in 1% agarose gels with formaldehyde and were transferred to Nylon membranes. EcoRI fragment of mda-5 cDNA (2.5 kb) was labeled with 32 P using a multiprime labeling kit (Boehringer Mannheim) and used to probe the transferred membrane. Nuclear run-on assays were performed as previously described ((17) Su et al., 1993, 1999). Probes used for nuclear run-on assays were prepared by RT-PCR and included the mda-5 5', 9-837 bp; mda-5 3', 2531-3365 bp; and GAPDH fragment.

In vitro translation: In vitro translation of mda-5 was performed with Novagen's STP3 kit using T7 RNA polymerase with 35S-Methionine as described in the manufacture's protocol. Template for transcription and translation was prepared by BamHI digestion followed by phenol/chloroform extraction of pGEM-7Zf(+)-mda-5. Proteins that were in vitro translated were resolved in 9% SDS-PAGE and detected by autofluorography.

Transient Transfection Assays: 293T cells were plated 1 day prior to transfection and grown to ~70% confluency. For intracellular localization, sterilized cover slips were placed in culture dishes and cells were seeded at 1 X 10⁵ cells/6 cm tissue culture plate.

Transient transfection assays were performed using SuperFect from Qiagen as described in the manufacturer's protocol. Ten μg of supercoiled plasmid DNA was transfected into 10 cm-tissue culture dish and cells were harvested two days after transfection.

Western Blot Analysis and Fluorescent Confocal Microscopy: Protein samples were prepared from transiently transfected cells by lysis in RIPA buffer supplemented with protease inhibitors. Twenty μg of protein was resolved in 9% SDS-PAGE and transferred to nitrocellulose membranes. MDA-5 fusion proteins were probed with either α -HA antibody (Boehringer Mannheim) or α -GFP antibody (ClonTech) and HRP-conjugated anti-Mouse IgG (Sigma) and detected by ECL (Amersham). For Fluorescence microscopy, cover glass containing transfected cells were washed with PBS and mounted onto glass slides with mounting medium. Cells were observed with fluorescent confocal microscopy.

Colony-Forming Assays: HO-1 melanoma cells were plated at 8×10^5 in a 6-cm dish one day prior to transfection. Five μg of supercoiled expression vector DNA was transfected into cells with SuperFect (Qiagen) as described above (18). Two days after transfection, cells were harvested by trypsinization and replated at 10^5 cells/6-cm dish with complete medium containing 750 μg G418/ml. From each transfection, three dishes were plated. The G418-containing media was replaced once a week for three week. Cells were stained with Giemsa and colonies containing more than 50 cells were counted.

Results

Cloning and Sequence Analysis of mda-5: Subtraction hybridization between a temporally spaced differentiation inducer, IFN- β + mezerein (MEZ), treated HO-1 human melanoma cDNA library and a temporally spaced untreated control HO-1 cDNA library identified a differentially expressed 0.3 kb EST, melanoma differentiation

associated gene-5 (mda-5) ((8) Jiang and Fisher, 1993). Northern blotting analysis indicated that the mda-5 EST hybridized with a mRNA species of ~3.8 kb in IFN- β + MEZ treated HO-1 cells ((8) Jiang and Fisher, 1993; Jiang et al., 1994). A full length mda-5 cDNA containing the complete open reading frame (ORF) was obtained using the C-ORF technique (Figure 1A) ((16) Kang and Fisher, 2000). The ORF of the mda-5 cDNA (3,362 bp excluding the poly A tail) extends from 169 to 3,246 bp and encodes a predicted protein of 1,025 amino acids with a molecular mass of 116.7 kDa. Two ATTTA motifs, which are commonly found in rapid turn-over RNA species, are present at positions 3,225 and 3,284. A poly A signal (AATAAA) is located 23 bp upstream of the poly A tail. A variant of mda-5, named mda-5p which contains an additional 202 bp attached to the 3' end of mda-5 was also identified by screening a placental cDNA library. Since the poly A signal for mda-5p is also located 23 bp upstream of its poly A tail, while the ORF remains constant, mda-5p is possibly an alternatively poly-adenylated variant of mda-5. The existence and tissue specific distribution of the two variant forms of mda-5 remains to be determined. However, RT-PCR analysis using HO-1 melanoma cells identified only mda-5 and not mda-5p.

Electronic sequence analysis of the MDA-5 protein using motif and profile scans of proteins presently in the protein database identified two conserved domains, a caspase recruitment domain (CARD) and an RNA helicase domain. The CARD domain which was defined by generalized profile alignment within the RAIDD and ICH-1 amino terminal regions, is present in various apoptotic molecules such as Mch6, ICE, ICH-2, c-IAP1, c-IAP2 and Ced-3. Current evidence suggests that the biological role of CARD is the recruitment of caspase to apoptotic signaling receptor complexes (19). The sequence alignment of N-terminal 50 amino acids (aa 125-174) of MDA-5 with other CARD-proteins reveals significant sequence homology at conserved amino acids of CARD (Figure 1B). MDA-5 displays the highest homology to the CARD region of RAIDD, which is involved in TNF-R1-mediated apoptotic signal transduction

(Figure 1C) (19). The C-terminal 100 amino acids (aa 722-823) of MDA-5 also show significant sequence homology to the RNA helicase C-terminal conserved domain, which is involved in RNA binding and unwinding of double-stranded RNA (Figure 1D) (20). In addition, as with other RNA helicases MDA-5 also contains an ATPase A and B motif (331-TGSGKT and 443-DECH) (Figure 1D) (20). However, MDA-5 has unique features in its helicase C-terminal motif and ATPase A motif. MDA-5 has ARGRA instead of the well-conserved YIHRIGRXR motif, which is critical for RNA binding in other RNA helicases (20). The ATPase A motif of MDA-5 (LPTGSGKT) is also different from the consensus sequence motif (A/GXXGXGKT) found in other RNA helicases (20). Moreover, MDA-5 is the first putative RNA helicase that retains both an altered RNA binding motif and an ATPase A motif. Screening of the SwissProt database for homologous sequences containing both of these motifs identified three yeast hypothetical ORFs encoding putative helicases (Gen Bank Accession Number Q09884, Q58900 and P34529). The unique features conserved in MDA-5 and these yeast proteins may signify that MDA-5 is a member of a new family of helicases. RNA helicases are known to be involved in diverse cellular processes including RNA splicing, RNA editing, RNA nuclear cytosolic transport, translation and viral replication by ATP-dependent unwinding of dsRNA (20). However, based on the unique structure of MDA-5, it is not possible at present to ascribe a biological role for this new molecule and new family of helicases.

Expression Pattern of mda-5: Since the mda-5 EST was cloned from differentiating HO-1 melanoma cells treated with IFN- β + MEZ, further studies were performed to define the type of molecules capable of regulating mda-5 expression. For this purpose, HO-1 cells were treated with a spectrum of agents affecting growth and differentiation in melanoma cells, including retinoic acid, mycophenolic acid, 12-O-tetradecanoylphorbol-13-acetate (TPA) and

3'-5' cyclic AMP. The effect of different types of IFNs and dsRNA (poly IC) and the effect of growth in serum-free medium on mda-5 expression was also evaluated by Northern blotting analyses. As seen in Figure 2A, steady-state mda-5 message level dramatically increases after treatment with IFN- β or dsRNA. IFN- α (Figure 4A) and IFN- γ also increase mda-5 transcript levels, but the magnitude of this effect is less than with IFN- β or dsRNA. Since the other reagents tested were not effective inducers of mda-5 expression, mda-5 may represent an interferon-responsive, primarily IFN- β -responsive, gene. Although MEZ treatment by itself does not induce mda-5 expression, it can augment mda-5 expression when used in combination with IFN- β and IFN- γ by approximately 3- to 5-fold, respectively (Figure 2A). A similar expression pattern of mda-5 as seen in HO-1 cells also occurs in human skin fibroblasts treated with IFN- β , IFN- γ or MEZ alone, or in combination (Figure 2B). Since MEZ co-treatment does not prolong the half-life of the mda-5 transcript (Figure 7A), augmentation of IFN- β or IFN- γ -induced mda-5 expression might occur at a transcriptional level, possibly by cross-talk between IFN and MEZ signaling pathways.

The induction of mda-5 expression by IFN- β also occurs in additional human melanoma cells and in normal and tumor cell lines of diverse origin treated with IFN- β (Figure 3A and 3B). The induction of mda-5 expression by IFN- β is independent of the status of p53 and RB. In this context, mda-5 is a bona fide IFN- β -responsive gene that can be induced in a broad spectrum of normal and tumor cell types irrespective of genetic variations present in the different tumor cell lines.

Since IFN signals through membrane receptor associated tyrosine kinases, the inducibility of mda-5 in HO-1 melanoma cells by ligands of other membrane tyrosine kinase receptors including IL-6, EGF, TGF- α , TGF- β , TNF- α and PDGF was studied by Northern blotting (Figure 4A and 4B). A direct comparison of the potency of induction of mda-5 between different sub-types of IFN was also evaluated

(Figure 4A and 4B). IFN- β displayed at least a 10-fold higher potency in mda-5 induction than IFN- α or IFN- γ (Figure 4A)

2E Among the other ligands of membrane receptors, TNF- α induced mda-5 expression at comparable levels as seen with IFN- α (Figure 4A). A similar pattern of induction of mda-5 expression was also apparent in early passage human skin fibroblasts (Figure 4B). Therefore, induction of mda-5 expression by IFN- α , IFN- β , IFN- γ and TNF- α is not unique to HO-1 cells, but rather may represent a general response of this gene in diverse cellular contexts. Considering that these agents can produce apoptotic signals in specific target cells, a possible role for MDA-5 in this process, through its CARD domain, is a possibility.

Treatment of HO-1 cells with IFN- β + MEZ results in terminal differentiation and a concomitant irreversible loss in cellular proliferation (Fisher et al., 1985). Terminal differentiation in the majority of inducer-treated cells occurs within 24 hr of treatment. In this context, the timing of mda-5 expression can provide a clue to the involvement of mda-5 in the induction of differentiation or in the maintenance of the differentiated phenotype. The timing of response to treatment can also provide insights into the mechanism of induction of mda-5. The timing of mda-5 expression was studied by Northern blotting and mda-5 message level began increasing within 2 hr of treatment with IFN- β or IFN- β + MEZ (Figure 5). The mda-5 message level peaks between 6-8 hr and the elevated level remains elevated over a 96 hr period. Although MEZ further increases mda-5 message level above that observed with IFN- β alone, it does not effect the timing of mda-5 expression. The fast kinetics of mda-5 induction suggested that mda-5 could be an early IFN- β -responsive gene and a major component mediating IFN- β induced growth inhibition and antiviral potency. In contrast, MEZ alone or serum-starvation induced lower levels of mda-5 expression and the timing of induction was delayed (first apparent after 48 hr) (Figure 5). Judging from the delayed kinetics of mda-5 induction by MEZ treatment and serum-deprivation, this induction

could be indirect resulting from the production of a cellular product(s) during the prolonged duration of treatment.

Organ-Specificity of mda-5 Expression: The organ-specific expression pattern of mda-5 was determined by hybridization of this gene with Poly A+ RNA from different organs immobilized on multiple tissue Northern blots (ClonTech) (Figure 6). Most organs expressed mda-5 at low levels except in the brain and lung in which expression was barely detectable. In testes, a 2.4 kb band instead of a 3.8 kb band present in the other organs was detected using the mda-5 probe. However, no organ showed noticeably higher levels of expression of mda-5. The highly inducible nature of mda-5 expression by IFNs, especially IFN- β , and TNF- α in diverse cell types and the relatively low basal message level in various organs strongly suggest that mda-5 could play a role in responses that are specific for IFN signaling, but less critical during normal physiological processes.

Mechanistic Aspects of mda-5 Induction: Steady state transcript levels of mda-5 were greatly increased during induction of terminal differentiation in HO-1 melanoma cells. The increased mda-5 message level could result from post-transcriptional control, such as message stabilization, or from enhanced transcription. The time course of decay in IFN- β and IFN- β + MEZ induced mda-5 mRNA levels were determined by blocking transcription with actinomycin D. A gradual temporal decrease in mda-5 transcript level after actinomycin D treatment was observed in both IFN- β and IFN- β + MEZ treated cells (Figure 7A). The half-life of mda-5 transcript in inducer treated HO-1 cells was approximately 5-6 hr. Since the basal level of mda-5 mRNA is too low to monitor quantitatively, effects of IFN- β and IFN- β + MEZ on posttranscriptional control of mda-5 message stability could not be determined. However, since actinomycin D treatment resulted in a decrease in mda-5 message level the induction of mda-5 by IFN- β and IFN- β + MEZ could result from changes in the rate of transcription of this gene. In

addition, the fact that the rate of decay in mda-5 message level is not markedly different in IFN- β and IFN- β + MEZ treated cells, mda-5 may also be controlled at a transcriptional level by MEZ when used in combination with IFN- β . Direct evidence for transcriptional control of mda-5 expression by IFN- β and IFN- β + MEZ treatment was provided by nuclear run-off assays (Figure 7B). Treatment of HO-1 cells with IFN- β greatly increased mda-5 transcription compared with only negligible levels of transcription in untreated or MEZ treated cells. IFN- β + MEZ treatment further enhanced the transcription level of mda-5 ~3 fold above that of IFN- β alone. These results document that the increased steady state levels of mda-5 message that result from IFN- β and IFN- β + MEZ treatment are the primarily the result of increased mda-5 transcription. As indicated above, MEZ does not increase transcription significantly, but MEZ in combination with IFN- β potentiates mda-5 transcription. Thus, the ability of MEZ + IFN- β to potentiate mda-5 mRNA levels most likely results from a synergistic increase in mda-5 transcription. Since MEZ is recognized as a weak activator of the enzyme protein kinase C (PKC), it is possible that a PKC-dependent augmentation of mda-5 transcription that is initiated by IFN- β signaling occurs following MEZ treatment.

Specific gene expression changes can be altered in response to a signaling event with or without prior protein synthesis. Certain gene expression changes (early response genes) including transcription factors and key signaling molecules do not require protein synthesis prior to their expression. By blocking protein synthesis with cycloheximide, a translation inhibitor, it is possible to determine whether induction of mda-5 expression by appropriate inducer treatment requires or is independent of prior protein synthesis (Figure 7C). Cycloheximide pre-treatment does not inhibit mda-5 steady-state mRNA levels induced by IFN- α , IFN- β , IFN- γ , TNF- γ and poly IC. Thus, mda-5 is primary response gene that is regulated by IFN- α , IFN- β , IFN- γ , TNF- γ and poly IC

treatment. In fact, in certain situations cycloheximide treatment further increased the level of induction of the mda-5 message. This finding suggests that cycloheximide treatment may inhibit the synthesis of a protein(s) that destabilizes mda-5 mRNA.

5 Expression of MDA-5 Protein and Intracellular Localization of MDA-5: To verify the authenticity of the mda-5 cDNA clone, in vitro translation experiments were performed. Expression of the mda-5 cDNA in an in vitro translation assay results in an encoded protein of ~120 kDa, close to the predicted size of the MDA-5 protein which is 116.7 kDa (Fig. 8A). The MDA-5 protein was tagged with either green fluorescent protein (GFP) or hemagglutinin (HA) and transiently transfected into 293 cells. Western blot analyses of cell lysates specifically detected an ~120 kDa protein (HA-tagged) and an ~160 kDa protein (GFP-tagged) in mda-5 cDNA transfected cells. These findings indicate that the cloned mda-5 cDNA does encode a protein of the expected size for this gene. Confocal fluorescence microscopy of 293T cells transiently transfected with GFP-mda-5 fusion protein demonstrated that the protein localizes in the cytosol (Figure 8C). A specific localization pattern within the cytoplasm of the GFP-mda-5 fusion protein was not observed. It is conceivable that the MDA-5 protein in the cytoplasm may play a role in the translation of specific mRNAs.

25 Effect of mda-5 on Colony Forming Ability of HO-1 Cells: HO-1 cells treated with IFN- β grow slower and display a noticeable enlargement in size in comparison with untreated cells. Since mda-5 is induced primarily by IFN- β , ectopic expression of mda-5 could mimic the effect IFN- β treatment and decrease proliferation. It is also conceivable that the CARD region of mda-5 could induce apoptotic signals and that ectopic expression of mda-5 could affect cell survival. To test for growth inhibitory or pro-apoptotic effects of mda-5 this gene was transfected and ectopically expressed in HO-1 cells and colony forming ability was determined (Figure 9). Compared with parental vector transfected cells, the number of

G418-resistant colonies in mda-5 expression-vector transfected cells was reduced by ~70%. A reduction in colony numbers that was less dramatic than the full coding frame of mda-5 versus parental vector transfected cells was also apparent when HO-1 cells were transfected with a deletion mutant of mda-5. Ectopic expression of the mda-5 deletion mutant (DN7, D310-484 including both ATPase motifs) caused a 47% reduction and transfection with a 2 kb antisense mda-5 (EB11) resulted in a 56% reduction in colony formation versus vector transfected controls. It appears that antisense mda-5 does not effectively block mda-5 expression. In fact, endogenous mda-5 expression was observed in cells transfected with antisense mda-5. It is possible that antisense mda-5 expression induces intracellular dsRNA formation and the dsRNA, in turn, induces endogenous mda-5 expression. In this way, ectopic expression of antisense mda-5 may affect colony-forming efficiency of HO-1 cells by directly altering the level of mda-5 in these cells. This is only one hypothetical explanation for this apparently paradoxical observation. Further studies are necessary to define the precise mechanism(s) by which ectopic expression of mda-5 exerts its effect on colony formatting ability of HO-1 cells.

Mda-5 Promoter Isolation and Characterization: Induction of mda-5 mRNA subsequent to treatment of human HO-1 melanoma cells with IFN- β indicated the strong likelihood of transcriptional regulation of gene expression based on Northern blot studies. To determine if the primary level of regulation was indeed transcriptional, a nuclear run-on experiment was performed (Fig. 7). Induction of mda-5 gene expression, as detected by a positive hybridization signal occurred in HO-1 samples that had been treated with IFN- β as opposed to a much lower signal in untreated cells, thereby validating the above hypothesis.

Having confirmed that induction of Mda-5 mRNA occurred primarily at the transcriptional level, it was decided that regulatory genomic

DNA sequences involved in this process should be isolated and characterized. To achieve this goal, a human genomic DNA library constructed in a Bacterial Artificial Chromosome vector (BAC, Genome Systems Inc.) was screened using the mda-5 cDNA as a probe.

Two rounds of screening were performed to obtain two overlapping clones that spanned the entire mda-5 genomic locus including several thousand bp of sequence upstream of the translational initiation codon. Mapping of the BAC clone containing the upstream region by restriction enzyme digestion, Southern blotting and sequence analysis permitted the identification of DNA fragments that contained potentially important regulatory sequences, which in the case of most protein coding genes lie upstream of the transcription initiation site. An approximately 7 kb HindIII fragment containing a partial first exon (including the initiator methionine) and approximately 6 kb of upstream sequence (Figure 10) was subcloned into the HindIII site of the promoterless luciferase reporter vector, pGL3 (Promega). Transfection of this construct into HO-1 cells in the presence or absence of IFN- β did not result in the production of Luciferase enzyme as determined by luminometric quantitation assays, necessitating a re-examination of the cloned DNA sequence. Conceptual translation of the cloned sequence when initiated from the mda-5 translation initiation ATG site (Figure 10) indicated that it would cause translational misreading and premature truncation of the Luciferase open reading frame with subsequent loss of enzymatic activity. To circumvent this problem, a small deletion of DNA sequences containing the mda-5 initiator methionine was carried out using a BstXI restriction digestion (Figure 10) followed by blunt ending the incompatible end overhangs and recircularization of plasmid by ligation.

The modified mda-5 reporter construct was transfected into parallel sets of HO-1 cells that were treated or not with IFN- β . Quantitation of luciferase activity indicated that this modified reporter containing a partially deleted Exon 1 and around 6 kb of

upstream sequences, showed ~10 fold higher luciferase activity in cells that had been treated with IFN- β compared to untreated controls. This level of induction was comparable to that seen with the endogenous gene in Northern blot analyses. It therefore appeared that the cloned regulatory genomic DNA sequence in the reporter construct contained the elements required for the regulation of the mda-5 gene. It was however, necessary to confirm that the cloned sequences contained all the regulatory elements involved in the transcriptional control of the endogenous cellular gene. Since HO-1 melanoma cells show a very low and variable transfection efficiency it initially proved very difficult to determine the activity of the transiently transfected reporter in a consistent way for variables such as kinetics of induction, optimal concentration of inducer and the identification of other potential activators. To circumvent this technical problem the mda-5 promoter construct was stably integrated into genomic DNA of HO-1 cells by co-transfection with a puromycin resistance plasmid and selection to isolate a clonal population of stable integrants. This selection procedure resulted in the production of several clones of which 48 were randomly picked for further analysis. Screening of these stable promoter clones by treatment with IFN- β indicated that an entire range from completely inactive to highly active, as measured by luciferase activity, had been obtained (Figure 11). Some of the clonal isolates showed induction levels similar to the endogenous gene (around 10 fold), while others displayed much higher induction (around 100-fold). It is a likely possibility that the clones showing higher levels of induction contain multiple copies of integrated plasmid that due to an additive effect show higher levels of activity. Two individual clones (#20 and #40) were selected for further analyses to determine if activation kinetics and overall responsiveness to inducer, as a measure to ascertain the completeness of the isolated promoter sequence, mimicked that previously observed for the endogenous gene. In the initial screen (Figure 11) the clone designated #20 showed a very low basal activity that on induction

was >1000 fold. It was therefore not included in the plot to permit the scale to represent the other clones (ranging from 0-150 fold induction) accurately. This clone on subsequent analysis displayed a very low basal activity but a much lesser final fold activation (Figure 12) than seen in the initial screen, but has maintained this property over several subsequent culture passages. To determine the induction kinetics of the promoter construct following treatment with IFN- β , a fixed number of cells (106 / 6 cm culture dish) was treated with inducer and assayed for luciferase activity compared with a parallel uninduced control sample, at various time-points following treatment (Figure 12). Irrespective of the final fold-induction of luciferase levels, which varied in an individual clone, the overall pattern of induction kinetics was almost identical and similar to that of the endogenous gene as determined by Northern blotting. Similarly, assays were performed to determine the range of sensitivity of detection of exogenously added Interferon levels as determined by a luciferase read out (Figure 13). The results of this assay closely paralleled that observed for the endogenous gene with measurable levels of 0.2 U of IFN- β being detectable. The promoter clone isolates were also used to determine responsiveness to different forms of IFNs including human IFN- α , β , and γ synthetic double stranded RNA (polyIC:IC; Amersham) and TNF- α (Figure 14A) using transient transfection assays with the reporter construct, in HO-1 melanoma cells. In addition, Clone #40 stable HO-1 cells were treated with human IFN- α A, - α b2, - α C, α D, α F, - α G, α H, - α I, - α J, - α A/D, PBL 1001, Bovine Tau, Ω and Human IFN- β (Figure 14B). Differential levels of responsiveness were seen dependent on the type of compound used, in general the Mda-5 promoter construct was most responsive to INF- β relative to other IFNs, comparable to the results obtained in Northern analyses with the endogenous cellular gene. As seen above, Mda-5 gene induction also occurs upon treatment of cells with synthetic double stranded RNA (poly IC:IC). Studies identical to those described for IFN- β were performed using double stranded RNA as an inducer with the stable HO-1 promoter clones. These

experiments generated results that were similar to endogenous gene induction for parameters including time and level of induction (Figure 15).

5 Discussion

Genes displaying differential expression as a function of induction of terminal differentiation by treatment of HO-1 melanoma cells with IFN- β + MEZ are classified into four subgroups based on their induction pattern (Jiang and Fisher, 1993). Mda-5 represents a Type I mda gene, which is induced by IFN- β and IFN- β + MEZ. Treatment with MEZ alone, which is a protein kinase C activator and a weak second-stage tumor promoter, does not induce mda-5 expression, but it potentiates mda-5 expression at a transcriptional level when combined with IFN- β . The inducible expression of 2'-5'oligoadenylate synthetase, another IFN-responsive gene, by IFN- α is augmented by TPA. Numerous evidence based on the use of PKC inhibitors indicate that the potentiation of IFN-gene expression by TPA involved activation of PKC, but the exact mechanism of this induction remains to be determined.

HO-1 melanoma cells treated with IFN- β increase in size, display slower growth kinetics and exhibit enhanced melanogenesis, but they do not undergo obvious morphological changes or cell death (Fisher et al., 1985). In contrast, MEZ, which does not induce mda-5, induces profound changes in the morphology of HO-1 cells, including the production of dendrite-like processes. Reagents that induce specific components of melanocytic differentiation in human melanoma cells, including all trans retinoic acid (RA), mycophenolic acid (MPA), cyclic-AMP (cAMP), dimethyl sulfoxide (DMSO) and TPA, also fail to significantly induce mda-5 expression. Therefore, it is possible that the primary role of mda-5 in the induction of terminal cell differentiation of HO-1 cells by IFN- β + MEZ is restricted to IFN- β -mediated suppression of cell proliferation.

Although IFN- α and IFN- γ significantly induce mda-5 expression, IFN- β was > 5-fold more effective in inducing mda-5 expression than either IFN- α or IFN- γ . IFN- β enhanced the expression of mda-5 in normal and tumor cell lines, including various melanoma cell lines regardless of their p53 or Rb status. Although mda-5 was undetectable in Northern blot of whole brain Poly A+ mRNA, mda-5 was detected and further induced by IFN- β treatment in cultured normal cerebellum and glioblastoma multiforme cells. In these contexts, mda-5 can be classified as an IFN- β -inducible gene. Both IFN- β and IFN- α share a common receptor (IFN-R1) and often display a similar pattern of gene expression changes, but the biological effects of these agents can be distinct. Mda-5 and a gene named INF-R1 are unique in that they display increased responsiveness to IFN- β than to IFN- α , which may involve IFN- β -specific cellular processes.

In addition to IFNs, the expression of mda-5 is also induced in both HO-1 melanoma and human skin fibroblast cells by TNF- α and poly IC. Both TNF- α and poly IC are established inducers of IFN- β gene expression. Based on these facts it is possible that TNF- α and poly IC may induce mda-5 gene expression by modulating IFN- β gene expression. In contrast, pretreatment with cycloheximide (CHX), a protein synthesis inhibitor did not inhibit mda-5 expression induced by TNF- α or poly IC, which suggests that these agents are direct inducers of mda-5. Poly IC directly activates PKR (dsRNA-activated interferon-inducible protein kinase) and induces class I MHC expression. TNF- α signaling was also found to be dependent on PKR activation. Alternatively or additionally, PKR which, independent of IFN receptor signaling, phosphorylates I κ B and transactivates NF κ B could be the mediator of TNF- α and poly IC-induced mda-5 expression. However, it is still possible that TNF- α and poly IC could stimulate secretion of preexisting IFN- β without the requirement of new protein synthesis.

IFNs were initially identified as molecules that provide immediate

protection against viral infection by eliciting an antiviral state in treated cells. IFN treatment evokes diverse responses depending on the target cell which include growth inhibition, changes in differentiation, induction or inhibition of apoptosis and changes in the expression of immune system modulating genes. IFN- β displays more potent growth inhibitory effects on normal melanocytes and melanoma cells, including HO-1, than IFN- α and IFN- γ . Interestingly, the growth inhibitory effect of IFNs in these cells correlates well with the level of induction of mda-5 expression. In addition, both inducers of mda-5, TNF- α and poly IC inhibit cell proliferation and induce apoptosis in a cell type specific manner. Induction of mda-5 by IFN- β is an early event, since the steady state mRNA message levels begin increasing within two hr of treatment. These results suggests that mda-5 may play a pivotal role in IFN- β -mediated suppression of cell proliferation.

Ectopic expression of mda-5 reduces the colony-forming capacity of HO-1 melanoma cells by ~70%. Considering the inefficient nature of transfection and the random incorporation of transfected genes into the cellular genome, the effect of ectopic mda-5 expression on colony-forming efficiency is quite dramatic. Surprisingly, the expression of a deletion mutant of mda-5 (deletion of the ATPase motif) also reduced colony formation (~47%), but was markedly less potent than the wild type mda-5 gene. Colony-forming efficiency is regulated by multiple parameters including inherent plating efficiency, and the growth inhibitory or toxic effect of the transfected gene product. Further studies are required to determine which factor is most critical in reducing the colony-forming efficiency of cells ectopically expressing mda-5.

Profile scans of the MDA-5 protein reveal putative CARD and RNA helicase motifs. Multiple sequence alignments of the CARD motif in MDA-5 using the ClustalW system indicate that this region most closely resembles the CARD of RAIDD, which is a component of

TNF-R1-mediated apoptotic signaling pathway and which contains both a death domain and a CARD motif. RAIDD interacts with RIP through its death domain and with ICH-1 (caspase-2) probably via its CARD motif. Although not as effective as IFN- β , TNF- α also induces mda-5 expression in HO-1 melanoma cells. In is therefore conceivable that mda-5 may interact with RAIDD and serve as a death effector molecule like ICH-1. A pro-apoptotic role of mda-5 is also supported by the dsRNA-dependent induction of this gene, which also activates PKR, a recognized molecule involved in growth suppression and apoptosis. However, a direct apoptotic role of mda-5 does not coincide with the effect of IFN- β on HO-1 melanoma cells, which results in growth suppression and not cell death. It is feasible that mda-5 may be a component of a death effector molecule, but by itself it lacks the capacity to trigger apoptosis. In this context, ectopic expression of mda-5 may result in growth inhibition and not apoptosis. It is also possible that the level of ectopic expression of mda-5 may determine whether this molecule is growth inhibitory or toxic. If this is true, expression of mda-5 by means of a adenovirus under the control of a strong promoter may produce sufficiently high levels of MDA-5 to induce cell death as opposed to growth inhibition.

Another distinct motif present in the MDA-5 protein is a RNA helicase signature domain, which spans the C-terminal half of this molecule. RNA helicase is a family of enzymes with a helicase motif, which potentially catalyzes NTP-dependent dsRNA unwinding activity. Not only are the core residues among the RNA helicases conserved, but also the spaces between these residues are retained in the different RNA helicases. Three main features characterize RNA helicases from the N- to C-terminal, an ATPase A motif(GXXGXGKT), an ATPase B motif (DEAD, DEAH or DEXH) and a critical domain for RNA interaction (HRIGRXXR) (Dong-chul, correct?). RNA helicases are classified into three subgroups based on their ATPase B motifs. RNA helicases are implicated in the

majority of steps associated with RNA processing and transcription, nuclear and mitochondrial RNA splicing, RNA editing, ribosomal biogenesis, nuclear cytosolic RNA export, degradation of nonsense RNA and RNA translation. Hence, RNA helicases affect many biological phenomena including cell differentiation, proliferation, development and viral life cycle. Although the RNA helicases are classified into three subgroups, the biological relevance of these groups remains to be defined. In addition, the enzymatic activity of many putative RNA helicases has not been confirmed, this could partly be because of the absence of the appropriate substrate and standard protocol due to the diversity of these enzymes.

Despite the well-conserved attributes of RNA helicases, MDA-5 contains four unique features that could mediate functional divergence. The CARD domain of MDA-5 in its N-terminal region is not found in any previously identified helicases, although the functional significance of this region is currently under investigation. The ATPase A motif of mda-5 is unique and contains LPTGSGKT as opposed to the sequences found in other RNA helicases (GXXGXGKT) and a mutation of the first glycine residue of murine eIF-4A to valine abolishes ATP binding ability. Since leucine is a non-polar amino acid as is valine, but it has a bulkier side chain than valine, MDA-5 may not bind ATP effectively and, hence, may be an ATPase defective helicase or it may require a different energy source and/or metals for activity. This property of MDA-5 may explain the reduction in colony forming efficiency by a expression of a mutant of mda-5 lacking this region of the MDA-5 protein. The HRIGRXXR motif which is critical for RNA binding in vitro is not well conserved in MDA-5 (ARGRI). The functional role of such sequence divergence in the MDA-5 protein remains to be determined. Three yeast hypothetical ORFs share specific features of MDA-5 including ATPase and RNA binding sites, but their biological function has not been ascertained. Complementation assays between these proteins can provide insights on functional and evolutionary relationship among these molecules.

Taken together, the distinctive features of the MDA-5 protein suggest that this molecule represents a member of a new family of RNA helicases. If this is the case, mda-5 may participate in degradation, translation or inhibition of translation of pro- or anti-apoptotic RNA molecules through its RNA helicase domain. Alternatively, mda-5 might be a signal transducer between IFN signals and the apoptotic machinery to prepare the cell for viral invasion and dsRNA accumulation. Localization of GFP-mda-5 fusion protein in the cytoplasm is not contradictory to this hypothesis.

The reporter isolate comprising the mda-5 promoter sequences driving the luciferase cDNA, based on comparison of the quantitation of luciferase assays to fold induction seen in Northern blot analyses of RNA from treated cells, closely mimicked the induction behavior of the endogenous gene. Activation of gene expression occurred primarily with IFN- β and double stranded RNA and to a lesser extent with other IFNs. This DNA sequence is therefore of considerable utility in understanding the regulation of mda-5 in particular and IFN- β inducible genes in general, also encompassing but not restricted to the analysis of compounds including synthetic small molecules that affect this pathway.

Due to the high level of sensitivity, technical simplicity and amenability toward semi-automation of luciferase assays, the mda-5 promoter clone isolates in HO-1 melanoma cells comprise an additional very useful detection and assay system for IFN levels with potentially significant advantages in terms of cost, convenience and reproducibility. Moreover due to the presence of the reporter construct within an in vivo biological context, in addition to the ability to quantitate the amount of exogenously added IFNs or determine responsiveness to specific IFNs, the system is utilizable in the study of compounds of a diverse nature that potentially impinge on the pathway with respect to multiple biological and pharmacological aspects. These include agonistic or antagonistic effects of a specific compound on the IFN pathway

combined with the general biological toxicity of that or a combination of compounds, potentially within the same assay itself. The promoter sequence may also be introduced into appropriate cells with an IFN relevant responsiveness similar to that achieved for HO-1 and studied parallel to those described in the HO-1 human melanoma system be performed.

In summary, mda-5 is a new IFN- β inducible putative RNA helicase containing a CARD motif. The expression of mda-5 is also induced by growth inhibitory and apoptotic signal molecules such as TNF- α and poly IC. Although it was not demonstrated in the present experiments, the ability of IFN- β and poly IC to induce mda-5 expression support the potential for viral induction of this gene. Ectopic expression of mda-5 significantly reduces colony-forming efficiency of HO-1 melanoma cells as expected from the inductive nature and sequence of this gene. The enzymatic activity of MDA-5 remains to be determined. As mentioned earlier, mda-5 may be a defective RNA helicase and a naturally occurring inhibitor of additional unknown helicases. If this is the case, it will be important to identify counterparts of mda-5 which display antiviral, proliferation inhibitory and/or apoptotic roles in cellular physiology. Of particular note is that viruses like hepatitis C virus (HCV) contain a helicase in their genome. Defining the enzymatic activity of MDA-5 may be achieved by modulating the experimental conditions, i.e., by changing reaction conditions including NTP and metal requirements, using potential stimulators like 2'-5' oligoadenylate, etc. Investigation of the physiological role and molecular basis of mda-5 action should provide important insights into the mechanism of cellular defense conferred by IFN against viral attack. This information should prove valuable in developing new strategies for inhibiting viral pathogenicity and for designing more effective antiviral therapeutics.

Example 2: Reporter cell lines

Reporter cell lines derived from the HO-1 human melanoma cell line containing genomically integrated copies of the Melanoma
5 Differentiation Associated Gene-5 (Mda-5) upstream promoter sequences.

A Bacterial Artificial Chromosome (BAC), human genomic library was screened to isolate sequences containing the Mda-5 gene. Two BAC
10 clones containing the coding and upstream sequences of the gene were isolated and characterized.

The complete intron/exon structure of the coding sequences has been determined. An approximately 6 kb fragment upstream of the
15 transcription start site was also isolated. This fragment was cloned into a promoterless luciferase vector (pGL3 Basic, Promega) and assayed by transient transfection assays for transcriptional activity. The activity displayed by this promoter construct was identical to that of the endogenous gene in terms of responsiveness
20 to inducers (recombinant human β -interferon or synthetic double stranded RNA, poly IC) and time kinetics of induction.

Several sublines containing stably integrated copies of the transcriptionally active luciferase plasmid in a HO-1 human
25 melanoma background was constructed. Independent clonally isolated colonies were expanded and assayed for luciferase activity in the presence of recombinant human β -interferon or synthetic double stranded RNA, poly IC. These clones exhibited luciferase activity similar to the endogenous gene except that the level of induction
30 varied from 10 to 100 fold, probably dependent on the number of integrated copies for each clone (the endogenous gene is induced about 10 fold). While these clones are most responsive to recombinant human β -interferon or synthetic double stranded RNA, poly IC they are also induced at lower levels by other interferons.

These cell lines may be used for:

A. Quantitation of biologically active amounts of interferon produced by various procedures;

5 B. In rapid high throughput screens to determine or distinguish the relative efficacy of compounds agonistic or antagonistic to the interferon biochemical and signalling pathway;

10 C. In a rapid high throughput screen to detect small molecules of potential pharmacological and therapeutic utility that synergizes or boosts cellular interferon pathways.

References

1. Fisher, P.B. and S. Grant, Effects of interferon on differentiation of normal and tumor cells. Pharmacology & Therapeutics, 1985. 27(2): p. 143-66.
2. Waxman, S., ed. Differentiation Therapy (Ares Serono Symposia Publications, Rome). Vol. 10. 1995. 1-531.
3. Jiang, H., J. Lin, and P.B. Fisher, A Molecular Definition of Terminal Differentiation in Human Melanoma Cells. Molecular Cellular Differentiation, 1994. 2(3): p. 221-239.
4. Waxman, S., G.B. Rossi, and T. F., The Status of Differentiation Therapy of Cancer, in The Status of Differentiation Therapy of Cancer, S. Waxman, G.B. Rossi, and T. F., Editors. 1988, Raven Press: New York, NY. P. 1-422.
5. Fisher, P.B., et al., Effects of combined treatment with interferon and mezerein on melanogenesis and growth in human melanoma cells. Journal of Interferon Research, 1985. 5(1): p. 11-22.
6. Jiang, H., et al., Gene Expression Changes Associated with Reversible Growth Suppression and the Induction of Terminal Differentiation in Human Melanoma Cells. Molecular Cellular Differentiation, 1993. 1(1): p. 41-66.
7. Jiang, H., S. Waxman, and P.B. Fisher, Regulation of c-fos, c-jun and jun-B Gene Expression in Human Melanoma Cells Induced to Terminally Differentiate. Molecular cellular Differentiation, 1993. 1(2): p. 197-214.
8. Jiang, H. and P.B. Fisher, Use a Sensitive and Efficient

Subtraction Hybridization Protocol for the Identification of Genes Differentially Regulated during the Induction of Differentiation, in Human Melanoma Cells. *Molecular Cellular Differentiation*, 1993. 1(3): p. 285-299.

5

9. Jiang, H., et al., Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. *Oncogene*, 1995. 11(12): p. 2477-86.

10

10. Jiang, H., et al., The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells. *Oncogene*, 1995. 10(9): p. 1855-64.

15

11. Jiang, H., et al., The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. *Proceedings of the National Academy of Sciences of the United States of America*, 1996. 93(17): p. 9160-5.

20

12. Lin, J.J., H. Jiang, and P.B. Fisher, Melanoma differentiation associated gene-9, mda-9, is a human gamma interferon responsive gene. *Gene*, 1998. 207(2): P.105-10.

25

13. Huang, F., et al., Differentiation induction subtraction hybridization (DISH): a strategy for cloning genes displaying differential expression during growth arrest and terminal differentiation. *Gene*, 1999. 236(1): p. 125-31.

30

14. Huang, F., et al., Identification and temporal expression pattern of genes modulated during irreversible growth arrest and terminal differentiation in human melanoma cells. *Oncogene*, 1999. 18(23): p. 3546-52.

35

15. Jiang, H., et al., The Melanoma Differentiation Associated Gene-6 (mda-6), Which Encodes the Cyclin-Dependent Kinase Inhibitor p21, May Function as a Negative Regulator of Human Melanoma Growth and Progression. *Molecular Cellular Differentiation*, 1996. 4(1): p. 67-89.

16. Kang, D.-C. And P.B. Fisher, C-ORF, A simple and Efficient Way to Clone Full Open Reading Frame. (Manuscript in preparation). 2000.

17. Su, Z.-z., Y. Shi, and P.B. Fisher, Subtraction hybridization identifies a transformation progression-associated gene PEG-3 with sequence homology to a growth arrest and DNA damage-inducible gene. *Proc. Natl. Acad. Sci. USA*, 1997. 94: p. 9125-30.

18. Sambrook, J., E. Fritsch, and T. Maniatis, *Molecular Cloning*. 2 ed. 1989, New York, NY: Cold Spring Harbor Laboratory Press.

19. Hofmann, K., P. Bucher, and J. Tschopp, The CARD domain: a new apoptotic signalling motif. *Trends Biochem Sci*, 1997. 22(5): p. 155-6.

20. Luking, A., U. Stahl, and U. Schmidt, The protein family of RNA Helicases. *Crit Rev Biochem Mol Biol*, 1998. 33(4): p. 259-96.

21. Rani, M.R.S., et al., Characterization of beta-R1, a gene that is selectively induced by interferon beta (IFN-beta) compared with IFN-alpha. *J Biol Chem*, 1996. 271(37): p. 22878-84.

What is claimed is:

1. An isolated nucleic acid comprising the sequence shown in SEQ ID NO: 1 encoding a Melanoma Differentiation Associated Gene -5 (Mda-5) polypeptide.
2. An isolated nucleic acid comprising a derivative of the sequence of SEQ ID NO:1 encoding a polypeptide which is functionally equivalent to Mda-5.
3. A fragment of the isolated nucleic acid of claim 1, wherein the fragment encodes a polypeptide having Mda-5 biological activity, wherein the biological activity is characterized by cancer cell growth suppression, apoptosis or anti-viral activity.
4. A nucleic acid which hybridizes to the DNA shown in SEQ ID NO:1 or the complementary strand thereof.
5. A vector comprising the nucleic acid of claim 1, 2 or 4.
6. A host cell comprising the vector of claim 5.
7. The host cell of claim 6, wherein the host cell is stably transformed with the vector of claim 5.
8. The host cell of claim 6, wherein the host cell is a tumor cell.
9. The host cell of claim 6, wherein the host cell is a melanocyte.

10. The host cell of claim 6, wherein the cell is an immortalized cell.

5 11. The host cell of claim 8, wherein the tumor cell is a melanoma cell, a neuroblastoma cell, an astrocytoma cell, a glioblastoma multiforme cell, a cerival cancer cell, a breast cancer cell, a lung cancer cell or a prostate cancer cell.

10 12. A method for determining whether a compound is an inducer of Mda-5 gene expression in a cell which comprises:

15 (a) contacting a cell with a first compound, wherein the cell comprises a nucleic acid encoding Mda-5 having the sequence shown in SEQ ID NO:1, or a functional equivalent thereof;

20 (b) measuring the level of either (i) Mda-5 mRNA produced or (ii) Mda-5 polypeptide expressed by the cell in the presence of the first compound;

25 (c) comparing the expression level of Mda-5 mRNA or polypeptide measured in step (b) with the level measured in the absence of the first compound, so as to determine whether the first compound is an inducer of Mda-5 gene expression in the cell.

30 13. The method of claim 12, wherein the first compound is a small organic molecule having a weight of about 5 kilodaltons or less.

14. The method of claim 12, wherein the first compound is an interferon- α , interferon- β , interferon- γ , TNF- α , a virus, or a double-stranded RNA molecule.

35 15. The method of claim 12, wherein the cell is a HO-1 human

melanoma cell.

16. The method of claim 12, wherein the cell is a melanoma cell,
a neuroblastoma cell, an astrocytoma cell, a glioblastoma
multiforme cell, a cerival cancer cell, a breast cancer cell,
a lung cancer cell or a prostate cancer cell.
17. The method of claim 12, wherein the level of Mda-5 gene
expression measured is from 10 to 1000 fold higher than the
level of Mda-5 gene expression measured in the absence of the
compound.
18. The method of claim 12, wherein presence of a second compound
which synergizes with the first compound which induces Mda-5
expression contacted with the cell in step (a).
19. The method of claim 12, wherein presence of a second compound
which is an antagonist of the first compound that induces Mda-
5 expression is admixed with the cell and first compound in
step (a).
20. The method of claim 18 or 19, wherein the second compound is
a small molecule of about molecular weight 10 kilodaltons or
less.
21. An isolated polypeptide having the amino acid sequence shown
in SEQ ID NO:2 encoding Mda-5.
22. An isolated antibody which specifically binds to the
polypeptide having the sequence shown in SEQ ID NO:2.
23. The antibody of claim 22, wherein the antibody is a monoclonal
antibody.
24. A method for treating cancer in a subject suffering therefrom

which comprises administering to the subject an effective amount of a compound identified by the method of claim 12 and a pharmaceutically acceptable carrier, so as to induce terminal differentiation of the cancer cells in the subject and thereby treat the cancer.

25. The method of claim 24, wherein the cancer is melanoma, neuroblastoma, astrocytoma, glioblastoma multiforme, cervical cancer, breast cancer, colon cancer, prostate cancer, osteosarcoma, or chondrosarcoma.

¹⁶
31. The method of claim 24, wherein the cancer is a cancer of the central nervous system of the subject.

¹⁷
32. The method of claim 24, wherein the administering is carried out via injection, oral administration, topical administration, adenovirus infection, liposome-mediated transfer, topical application to the cells of the subject, or microinjection.

¹⁸
33. The method of claim 24, wherein the carrier is an aqueous carrier, a liposome, or a lipid carrier.

²⁹
34. An assay to determine whether a compound modifies enzymatic activity of an Mda-5 polypeptide which comprises monitoring enzymatic conversion of a substrate to an endproduct.

³⁰
35. The assay of claim 34, wherein the enzymatic activity monitored is helicase activity.

Melanoma Differentiation Associated
Gene - 5 Promoter and Uses Thereof

Abstract of the Disclosure

5 The invention provides for an isolated nucleic acid encoding Mda-5 polypeptide as shown in SEQ ID NO:1. A polypeptide having the sequence shown in SEQ ID NO:2. The present invention provides for an isolated *Mda-5* promoter capable of directing transcription of a
10 heterologous coding sequence positioned downstream therefrom, wherein the promoter is selected from the group consisting of: (a) a promoter comprising the nucleotide sequence shown in SEQ ID NO:3 ; (b) a promoter comprising a nucleotide sequence functionally equivalent to the nucleotide sequence shown in SEQ ID NO: 3; and
15 (c) a promoter comprising a nucleotide sequence that hybridizes to a sequence complementary to the promoter of (a) or (b) in a Southern hybridization reaction performed under stringent conditions. The invention provides for a host cell comprising the recombinant expression construct as described herein. The
20 invention further provides for a method for treating cancer in a subject suffering therefrom which comprises administering to the subject an effective amount of a pharmaceutical composition which comprises a recombinant expression construct comprising: (a) a nucleic acid molecule that encodes a selected polypeptide; and (b)
25 an *Mda-5* promoter nucleotide sequence operably linked to the nucleic acid molecule of element (a), wherein the coding sequence will be transcribed and translated when in a host cell to produce the selected polypeptide, and the *Mda-5* promoter is heterologous to the coding sequence and a pharmaceutically acceptable carrier.

GCW GOC GOG GUT GAG AGC GCT GTC GAC AGC GTC GTC ATT GTC AGG GAG AGA GCG GTC AGC
GCT GCT TCT TTA TPT GAG GAG GAG GAG GAG GAG GAG GAG GAG GAG GAG GAG GAG GAG GAG
GAG GAG GAG GAG GAG GAG GAG GAG GAG GAG GAG GAG GAG GAG GAG GAG GAG GAG GAG
TAT TCC AGA GAG GAG AAT TTC GOC TAT TCC GTC TAT TCC TCC AGG GOC AGG GTC AGA AGT
Y S T D E F R Y L C S C F R A R V K M
TAC ATT CAG GTC GAG GTC GTC GAG TAC TCC TCC TCC TCC TCC TCC TCC TCC TCC TCC TCC
Y I Q V E P V L D Y L T F L P A E V X E
CAG ATT CAG AGG AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC
Q I Q R T V A T S G S M Q A V S L L L L S
ACC TTS GAG AGA GTC TTS GAG CTT GTC TTS GAG CTT GTC TTS GAG CTT GTC TTS GAG CTT GTC
T L E K F V S L W T F V S A L R
AGA AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC
S E S S L A R Y H P S D L D L L L L L
CCA TTS TTS GAG AGC GTC GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT
P S F E A H D E Y L Q L M L L L L L
GTC TTS GAG AGC GTC TTS GAG AGC GTC TTS GAG AGC GTC TTS GAG AGC GTC TTS GAG AGC
L V D K L L L V R D K C M E S E L L L
ACA ATT GAG AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC
T I E D E R I A E S E S G V
AGA GAG GTC TTA AGA AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC
R E L E R I V O E S E S F L S
CTT GTC CAA AGA AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC
L R O T G S E S L V O E L T G S D C S E
AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC
S S A E I E S L S O V D G P Q V E S Q L
CTT TCA AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC
L S T T V Q P H L E K E V W G H S S E
TCA AGA TCA TCT TTS GAG AGC TCT TTS GAG AGC TCT TTS GAG AGC TCT TTS GAG AGC
S E S S F A D S S V V S E S D S L E
GGA AGT GTC AGC TCT TTA GAT GAG AGT GTC AGA GAT AGC AGC AGC AGC AGC AGC AGC
G S V S L E S H S H S G S D
GOC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC
G T N G S D S D E H S V A A A S P E P
GAG GTC GAG AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC
E L Q L R P Y G N E S V A Q P A L E G K S
AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC
I I I C L L P T G S G K T R V A V Y I A K
GAT GAT TTA GAG AGC AGA AGA AGA AGC TTS GAG AGC AGA AGA AGA AGA AGA AGA AGA
D H L D K K A E S E K V L V E
AGA GTC GTC GTC GTC GTC GTC GTC GTC GTC GTC GTC GTC GTC GTC GTC GTC GTC
R V L L V L P R K E P P
TAT GTC GTC GTC GTC GTC GTC GTC GTC GTC GTC GTC GTC GTC GTC GTC GTC
Y R V I G L S G D T Q L K I S P E V V
AGA GTC GTC GTC GTC GTC GTC GTC GTC GTC GTC GTC GTC GTC GTC GTC GTC
K S C D I I I S T A Q I L E S S L L L L
GAT AGT GAG AGC GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT
E H G V E Q D L I D F A I A D
TCT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT
C H E S E A V Y S E I M S V L M G
AGA TTS AGA AGC AGT AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC
K L R E S E K P L L P O A I R
GTC GTC GTC GTC GTC GTC GTC GTC GTC GTC GTC GTC GTC GTC GTC GTC GTC
L G L T A S P G V G G A T K Q A K A E E
CAG ATT TTA AGA GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT
H I L E L C A S L D A F T I K T V K E S
CTT GAT CAA GTC AGA AGC AGA AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC
L D Q L E S I G E P K F A I A D
AGC AGA GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT
T R E D P F E S E L L E I M S T Q T Y
TCT CAA AGT AGT AGT AGT AGT AGT AGT AGT AGT AGT AGT AGT AGT AGT AGT AGT
C Q H S P M E D F G S Q P V E Q M A I Q
AGC AGA AGA AGC AGC AGA AGA AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC
M E K K A A K E G S R K E R V C A S B L
AGA AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC
R K Y S E A L Q I S D T I R M I D A V T
GAT GTC AGA AGC TCT TAT AGT AGA AGC AGA AGT AGC AGC AGC AGC AGC AGC AGC
S L E T F T H E E D K E F A I E D
AGT AGT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT
S D E S G D E Y C D G D E S D D L E
AGA GTC TTS AGA GTC AGA AGC AGA AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC
K P L K L D E T D E F L M Y L F F R E S
AGA AGT TTS AGA AGC GTC AGC AGA AGC AGA AGC AGA AGC AGA AGC AGA AGC AGA
K N L K R L A E S P E Y S E S E K L T R L
AGA AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC
R S T I M E Q Y T R T E S B A R G I I F
AGA AGA AGC AGA AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC
T K T R S A V A L S Q M I T S E E E
GAT GTC AGA GTC AGA AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC
A E V G V S A V L I G A H S S E E
GOC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC
P N Y Q S E Q F E V S R F R S G K I S
GTC GTC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC
L L I A T T V A E S O L D I E S C S I V
ATC GTC GAT GTC GTC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC
I R Y G L V T S E I A N V Q A R G R A R
GTC GAT GAG AGC AGC TAT GTC GTC GTC AGC AGC AGC AGC AGC AGC AGC AGC
A D E S S T V L V A S G S G V I E S
ACA GTC AGT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT
T V H D F R E K S M V K A I S C V Q S H
AGA CCA GAG GAT GAT GAT AGT AGT TTS AGA TTA GAT AGC AGA AGT AGA AGC AGC
K P E E Y A H K I L E L Q M Q Q F R E S
AGA AGT AGA AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC
K H E T K R S I A K R Y R S S P S L I T
TTC GTC TTS AGA GTC GTC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC
F L C K E S C V L A C S G E D I H V I E
AGA AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC
K N H S V M F S E F E L V E R E
AGA AGC GTC AGA AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC
R A L Q E K C A D Y D I H G E I I C K
GOC GAG GTC TTS AGA AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC
S Q A M G T N M V S E G L D L C L K I
AGA AGT TTS AGA GTC TTS AGA AGT AGT TCA AGC AGC AGC AGC AGC AGC AGC
R S F V V V F K S S S T K K Q Y K E W V
AGA TTA GTC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC AGC
E L P I T F P S E L D V S E C C L F D E
GAT TAT GAT TTS AGA AGC GTC TTS AGA AGA TTA TCA GTC AGC AGC AGC AGC
D
TGA TTA AGT TAT TCA TTA TAT TAT TAT TAT TAT TAT TAT TAT TAT TAT TAT
CTC TG

Fig. 1A

CATTGAACTC TTTTAAAGAA CACAATATAT TANGCATTAT CCATCTTATT
GTTGGGCAGA GGTAAGGAAA ATNTACCAAT AATTTTCATT AGTGTGGAGC
ATTATANTCC TGTGAAAGA ATGCTGAAGT ACAAATGAGA ATCCAAAGTA
CCAGTCTCAG TTCTGTCACT AATTTTCAGA **ATAAAATTAG** GCAAATCAGT
TC

fig 10

```

JH-2      -MAGNHRKKKPLKVLKSLGKDFLTGVLDNLVBQNVLNWKEEKKKKYYD-AKTEDKVRVMA 58
JE        -MADKVLKERRKLFIRSMGEGTINGLDELQTPVLNKEEMKVKREN-ATVMDKTRALI 58
JP1-453   -MADDDLKSLIRKNNRMALFQQLTCVLPILDNLLKANVINKEQEHDIKQK--TQIPLQARELI 58
JP2-439   -ESNDLLLRKNNRMALFOHLTCVLPILDNLLKAGIINKEQEHDIKQK--TQIPLQARELI 58
JH-1      -MHPHHQETLKNRNVVLAKQLLLSLLLEHLLLEKDIITLEMRELIQAK--VGSFSGQNVRELI 57
la5-125   -----LVDRKLLVRDVLDKCMEEELLTIEDRNRIAAAENNGNESGVRELI 44
AIDD      -EARDKQVLRSLRLLELGAELVLEGLVLYQYLYQEGILTENHIQBINQA--TTGLRKTMLLL 58
          :* : : : :
JH-2      DSMQEKQRMAGQMLLQTTFFNIDQISP-----NKKAHFNMZAGPFESGESTDALKLCPE 112
JE        DSVIPKGAQACQICITYICEEDSVLAGTLGLSAAPOAVQDNPAKPTSSGSEGNVRLCSLE 118
JP1-453   DTILVKGNAAANIFKNCLKEIDSTLY-----KNLFVDKNNKYYIP---TEDVSGLSLEE 108
JP2-439   DTILVKGNIAATVFRNSLQBAEAVLY-----EHLFVQQDIKYIP---TEDVSGLSLEE 107
JH-1      NLLPKRGQPAFADFCEALRETKQGHLED--MLLTTLGSLQHVLPPLSCDYDLSLPPFPVE 115
la5-125   KRIVQK----- 50
AIDD      DILPSEGGPKAFDTFLDSLQEPFVVERK-----LKKAREEAMTDLP---AGDRLTGIPSH 109
          : :

```

Fig. 1c

```

F4A1 -----MSASQDSRSRDNGP----- 14
8RNAhelicase -----MSGYSSDRDRGRDRGFGAPRFGG----- 23
la-5 LLLSTLEKGVWHLGWTRFVFEALRRRTGSPLAARYMNPBELTDLPSPSFENAHDEYLLQLNL 120
      :.. * .

F4A1 -----DGME-----PEGVIESNWN----- 28
8RNAhelicase -----SRAGPLSGKKFGNF-----GEKLVKKKNWLD 49
la-5 LQPTLVDKLLVRDVLDCMEELLTIEDRNRIAAENNGNESGVRELLKRIVQKENWFS 180
      : : : :

F4A1 -----PKFEKNFYQEHFPLARRTAQEVETYRRSKEITVRGH 87
8RNAhelicase EL----- 87
la-5 FLNVLRTQGNNELVQELTGSDCSESNAELENLSQVDGPQVEQLLSTTVQPNLEKEVWGM 240

F4A1 -----EIVDSFDDMNL-----ESLLRGIYAYG 51
8RNAhelicase NCPKPVLFNFYEANFP-----ANVMDVIARQN 113
la-5 ENNSSSESFADSSVSVSESDTSLAEGSVSCLDES LGHNSNMGSDSGTMGSDSDEENVAARA 300
      : * : :

F4A1 FEKP-----SAIQQRAILPCIKGYDVIAQAQSGTGKTATFAISILQQIELD-----LKATQ 102
8RNAhelicase FTEP-----TAIQAQGWPAVALSGLDVGVQAQTGSGKTLGYLLPAIVHINHQPFLERGGDGP 169
la-5 SPEFELQIRFYQMEVAQPALEGKNIICLPTGSGKTRVAVYIAKDHLDKK-----KASEPGK 358
      : * : : : : : : : : : : :

F4A1 ALVLAPTRELAQQIQ----- 117
8RNAhelicase CLVLAPTRELAQQVQ----- 184
la-5 VIVLVNKKVLVLEQLFRKEFPQFLKKWYRVIGLSGTQLKISFPEVVRSCDIISTAQILE 418
      : * : : * : :

F4A1 -----KVV 120
8RNAhelicase -----QVA 187
la-5 NSLLNLENGEDAGVQLSDFSLLIIDECHHTNKAEVYNNIMRHYLMQKLNKNNRLEKRPV 478
      : .

F4A1 MALGDYMGASCHACIGGTNVRAEVQKLQMEAPHIIVGTGPRVFDMLNRRYLSPKYIKMFV 180
8RNAhelicase AKYCRACRLKSTCIYGGAPKGPQIRDLEGR-VEICIAATFGLRIDFLECGKTNLRRTTYLV 246
la-5 IPLPQLILGTASPGVGATKQAKAEHILKLCANLDAFTIKTVKENLDQLKNQIQEPCKK 538
      : : * : : : : : : : : : : :

F4A1 LDEADEMLSRGFKDQIYDIPQKLSNWTQVLLSATMPSDVLEVTKKFMRDPIRILVKKEE 240
8RNAhelicase LDEADRLMDGFEQIRKIVDQIRFDRQTLHWSATWPKFVRLAEDFLKDYIHIIMIGALE 306
la-5 FAIADATREDPFKEKLLIIMTRIQTTCQMSFMSDFGTQPYEQWAIQMEKKAARKGNRKR 598
      : : * : : : : : : : : : : :

F4A1 LTLLEGIRQF-----YINVERHEWKLDTLCD--- 265
8RNAhelicase LSAHHHILQ-----IVDVCHDVEKDEKILR--- 331
la-5 VCAEHLRKYNEALQINDTIRMIDAYTHLETFFYNEEKDKKFAVIRDDSDGDDDEYCDGDE 658
      : : : : : : : : : : : :

F4A1 -----LYETLTIT--- 273
8RNAhelicase -----LMEIMSEKE--- 341
la-5 DEDDLKKPLKLDSTDRFLMTLFPENNKMLKRIENPEYENEKTLKRLNTIMEQYTRTES 718
      : *

F4A1 -QAVIFINTRR-----XVDWLTEKMEHARDPTVSAMHGD-----MDQKERDVIMREF 318
8RNAhelicase NKTIIVEVETKR-----RCDELTRKMRRDGWPFAMCIHGD-----KSQOERDNLVNEF 387
la-5 ARGIIFTTKRQSAVALSQWITENEKFAEVGVKAHHLGAGHSSEFKPMTQNEKFEVISKF 778
      : : * : : : : : : : : : : :


F4A1 RSGSSRVLTITDLLARGIDVQQVSLVINVDLPTNRENYIHRIGR-----GRFGRKG 371
8RNAhelicase KHGKAPILLATDVASRGLDVEDVKFVINVDYFNSSDYIHRIGR-----ARSTKTG 440
la-5 RTGKINLLIATTVAEGLDIKECNIVIRYGLVTNEIAHWQARGARADESTYVLVAHSGS 838
      : * : * : : : * : : : : : : : : : :

F4A1 AINMVTEEDKRTLRLDIETFYNTSIEEMPLNVADLI----- 406
8RNAhelicase AYTFPTPNNIKQVSDLSVLRKANQAINPKLLQLVEDRSGSRSGRGGMKDDRRDRYSAG 500
la-5 GVIEHTEDPREKMMYKAHCVOQNMKFEYAHKILELQMQSIMEKKMKTRKRIAKHYKN 898
      : : : : : : : : : : : :

```

2.10

A.



B.





Figure 2

A.



B.





Figure 3






Figure 5






Figure 6

A.



B.



C.






Figure 7


A.




B.



C.





09345003.102600

[illegible]

1021 -----+----- 1036

Figure 10

Figure 11





Figure 12





Figure 13






Figure 14 A








Figure 14B

Figure 15



[illegible]

Declaration and Power of Attorney

Page 2

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below:

<u>Provisional Application No.</u>	<u>Filing Date</u>	<u>Status</u>
<u>N/A</u>		

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States Application(s), or Section 365(c) of any PCT International Application(s) designating the United States listed below. Insofar as this application discloses and claims subject matter in addition to that disclosed in any such prior Application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date(s) of such prior Application(s) and the national or PCT international filing date of this application:

<u>Application Serial No.</u>	<u>Filing Date</u>	<u>Status</u>
<u>N/A</u>		

And I hereby appoint

John P. White (Reg. No. 28,678); Christopher C. Dunham (Reg. No. 22,031); Norman H. Zivin (Reg. No. 25,385); Jay H. Maioli (Reg. No. 27,213); William E. Pelton (Reg. No. 25, 702); Robert D. Katz (Reg. No. 30,141); Peter J. Phillips (Reg. No. 29, 691) Wendy E. Miller (Reg. No. 35, 615); Richard S. Milner (Reg. No. 33,970); Robert T. Maldonado (Reg. No. 38,232); Paul Teng (Reg. No. 40, 837); Gary J. Gershik (Reg. No. 39,992); Richard F. Jaworski (Reg. No. 33,515); Elizabeth M. Wiecewski (Reg. No. 42,226); and Pedro C. Fernandez (Reg. No. 41,741)

and each of them, all c/o Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, New York 10036, my attorneys, each with full power of substitution and revocation, to prosecute this application, to make alterations and amendments therein, to receive the patent, to transact all business in the Patent and Trademark Office connected therewith and to file any International Applications which are based thereon under the provisions of the Patent Cooperation Treaty.

Declaration and Power of Attorney

Page 3

Please address all communications, and direct all telephone call, regarding this application to:

John P. White Reg. No. 28,678
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
Tel. (212) 278-0400

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first joint inventor Paul B. Fisher

Inventor's signature _____

Citizenship United States of America Date of signature _____

Residence 15 Gordon Place, Scarsdale, New York 10583, U.S.A.

Post Office Address same as above

Full name of sole or first joint inventor Dong-Chul Kang

Inventor's signature _____

Citizenship Korea Date of signature _____

Residence 200 Union Avenue, Apt. A, Rutherford, New Jersey 07070, U.S.A.

Post Office Address same as above

Full name of sole or first joint inventor Rahul V. Gopalkrishnan

Inventor's signature _____

Citizenship India Date of signature _____

Residence 302 West 79 Street, Apt. 2A, New York, New York 10024, U.S.A.

Post Office Address same as above